In Silico Study of Human Gap Junction Beta-2 Protein by Homology Modeling.
('In', 'In', 'IN', 'B-PP', 'O')
('Silico', 'Silico', 'NNP', 'B-NP', 'O')
('Study', 'Study', 'NNP', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('Human', 'Human', 'JJ', 'B-NP', 'B-protein')
('Gap', 'Gap', 'NN', 'I-NP', 'I-protein')
('Junction', 'Junction', 'NN', 'I-NP', 'I-protein')
('Beta-2', 'Beta-2', 'NN', 'I-NP', 'I-protein')
('Protein', 'Protein', 'NN', 'I-NP', 'I-protein')
('by', 'by', 'IN', 'B-PP', 'O')
('Homology', 'Homology', 'NNP', 'B-NP', 'O')
('Modeling.', 'Modeling.', 'NNP', 'I-NP', 'O')
Asp66his, Asp54Lys, and Asp50Asn are mutations in connexin 26 that are observed in the clinic and give rise to autosomal dominant syndromes.
('Asp66his,', 'Asp66his,', 'NN', 'B-NP', 'O')
('Asp54Lys,', 'Asp54Lys,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('Asp50Asn', 'Asp50Asn', 'NN', 'I-NP', 'O')
('are', 'be', 'VBP', 'B-VP', 'O')
('mutations', 'mutation', 'NNS', 'B-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('connexin', 'connexin', 'NN', 'B-NP', 'O')
('26', '26', 'CD', 'I-NP', 'O')
('that', 'that', 'WDT', 'B-NP', 'O')
('are', 'be', 'VBP', 'B-VP', 'O')
('observed', 'observe', 'VBN', 'I-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('clinic', 'clinic', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('give', 'give', 'VBP', 'B-VP', 'O')
('rise', 'rise', 'NN', 'B-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('autosomal', 'autosomal', 'JJ', 'B-NP', 'O')
('dominant', 'dominant', 'JJ', 'I-NP', 'O')
('syndromes.', 'syndromes.', 'NN', 'I-NP', 'O')
They are the result of point mutations in the human gap junction β2 gene.
('They', 'They', 'PRP', 'B-NP', 'O')
('are', 'be', 'VBP', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('result', 'result', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('point', 'point', 'NN', 'B-NP', 'O')
('mutations', 'mutation', 'NNS', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('human', 'human', 'JJ', 'I-NP', 'O')
('gap', 'gap', 'NN', 'I-NP', 'O')
('junction', 'junction', 'NN', 'I-NP', 'O')
('β2', 'β2', 'CD', 'B-NP', 'O')
('gene.', 'gene.', 'NN', 'I-NP', 'O')
In order to investigate the structural mechanism of Bart-Pumphrey Syndrome, Keratitis-IchthyosisDeafness Syndrome, and Vohwinkel Syndrome, homology modeling was carried out.
('In', 'In', 'IN', 'B-SBAR', 'O')
('order', 'order', 'NN', 'O', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('investigate', 'investigate', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('structural', 'structural', 'JJ', 'I-NP', 'O')
('mechanism', 'mechanism', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('Bart-Pumphrey', 'Bart-Pumphrey', 'NNP', 'B-NP', 'O')
('Syndrome,', 'Syndrome,', 'NNP', 'I-NP', 'O')
('Keratitis-IchthyosisDeafness', 'Keratitis-IchthyosisDeafness', 'NNP', 'I-NP', 'O')
('Syndrome,', 'Syndrome,', 'NNP', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('Vohwinkel', 'Vohwinkel', 'NNP', 'B-NP', 'O')
('Syndrome,', 'Syndrome,', 'NNP', 'I-NP', 'O')
('homology', 'homology', 'NN', 'I-NP', 'O')
('modeling', 'modeling', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('carried', 'carry', 'VBN', 'I-VP', 'O')
('out.', 'out.', 'JJ', 'B-ADJP', 'O')
Asp66 has direct contact with Asn62 by two hydrogen bonds in the wildtype protein, and in Asp66His, the biggest change observed is a tremendous energy increase caused by hydrogen bond breakage to Asn62.
('Asp66', 'Asp66', 'NN', 'B-NP', 'B-protein')
('has', 'have', 'VBZ', 'B-VP', 'O')
('direct', 'direct', 'JJ', 'B-NP', 'O')
('contact', 'contact', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('Asn62', 'Asn62', 'NN', 'B-NP', 'B-protein')
('by', 'by', 'IN', 'B-PP', 'O')
('two', 'two', 'CD', 'B-NP', 'O')
('hydrogen', 'hydrogen', 'NN', 'I-NP', 'O')
('bonds', 'bond', 'NNS', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('wildtype', 'wildtype', 'JJ', 'I-NP', 'B-protein')
('protein,', 'protein,', 'NN', 'I-NP', 'I-protein')
('and', 'and', 'CC', 'B-PP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('Asp66His,', 'Asp66His,', 'NN', 'B-NP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('biggest', 'big', 'JJS', 'I-NP', 'O')
('change', 'change', 'NN', 'I-NP', 'O')
('observed', 'observe', 'VBN', 'B-VP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('tremendous', 'tremendous', 'JJ', 'I-NP', 'O')
('energy', 'energy', 'NN', 'I-NP', 'O')
('increase', 'increase', 'NN', 'I-NP', 'O')
('caused', 'cause', 'VBN', 'B-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('hydrogen', 'hydrogen', 'NN', 'B-NP', 'O')
('bond', 'bond', 'NN', 'I-NP', 'O')
('breakage', 'breakage', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('Asn62.', 'Asn62.', 'NN', 'B-NP', 'O')
Shifts in the side chain and new hydrogen bond formation are observed for Lys54 compared to the wild-type protein (Asn54) and result in closer contact to Val84.
('Shifts', 'Shift', 'NNS', 'B-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('side', 'side', 'NN', 'I-NP', 'O')
('chain', 'chain', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('new', 'new', 'JJ', 'B-NP', 'O')
('hydrogen', 'hydrogen', 'NN', 'I-NP', 'O')
('bond', 'bond', 'NN', 'I-NP', 'O')
('formation', 'formation', 'NN', 'I-NP', 'O')
('are', 'be', 'VBP', 'B-VP', 'O')
('observed', 'observe', 'VBN', 'I-VP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('Lys54', 'Lys54', 'NN', 'B-NP', 'B-protein')
('compared', 'compare', 'VBN', 'B-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('wild-type', 'wild-type', 'JJ', 'I-NP', 'B-protein')
('protein', 'protein', 'NN', 'I-NP', 'I-protein')
('(Asn54)', '(Asn54)', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('result', 'result', 'VBP', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('closer', 'close', 'JJR', 'B-NP', 'O')
('contact', 'contact', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('Val84.', 'Val84.', 'NN', 'B-NP', 'B-protein')
Asp50Asn causes a significant decrease in bond energy, and residual charge reversal repels the ion and metabolites and, hence, inhibits their transportation.
('Asp50Asn', 'Asp50Asn', 'NN', 'B-NP', 'O')
('causes', 'cause', 'VBZ', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('significant', 'significant', 'JJ', 'I-NP', 'O')
('decrease', 'decrease', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('bond', 'bond', 'NN', 'B-NP', 'O')
('energy,', 'energy,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('residual', 'residual', 'JJ', 'B-NP', 'O')
('charge', 'charge', 'NN', 'I-NP', 'O')
('reversal', 'reversal', 'NN', 'I-NP', 'O')
('repels', 'repel', 'VBZ', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('ion', 'ion', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('metabolites', 'metabolite', 'NNS', 'I-NP', 'O')
('and,', 'and,', 'CC', 'O', 'O')
('hence,', 'hence,', 'NN', 'B-NP', 'O')
('inhibits', 'inhibit', 'VBZ', 'B-VP', 'O')
('their', 'their', 'PRP$', 'B-NP', 'O')
('transportation.', 'transportation.', 'NN', 'I-NP', 'O')
Such perturbations are likely to be a factor contributing to abnormal functioning of ion channels, resulting cell death and disease.
('Such', 'Such', 'JJ', 'B-NP', 'O')
('perturbations', 'perturbation', 'NNS', 'I-NP', 'O')
('are', 'be', 'VBP', 'B-VP', 'O')
('likely', 'likely', 'JJ', 'B-ADJP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('factor', 'factor', 'NN', 'I-NP', 'O')
('contributing', 'contribute', 'VBG', 'B-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('abnormal', 'abnormal', 'JJ', 'B-NP', 'O')
('functioning', 'functioning', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('ion', 'ion', 'NN', 'B-NP', 'O')
('channels,', 'channels,', 'NN', 'I-NP', 'O')
('resulting', 'result', 'VBG', 'B-VP', 'O')
('cell', 'cell', 'NN', 'B-NP', 'O')
('death', 'death', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('disease.', 'disease.', 'NN', 'B-NP', 'O')
Hearing impairment or hearing loss is a full or partial decrease in the ability to perceive sounds, induced by various biological (Tremblay and Ross, 2007), environmental (Eyken et al., 2007), and genetic factors.
('Hearing', 'Hear', 'VBG', 'B-VP', 'O')
('impairment', 'impairment', 'NN', 'B-NP', 'O')
('or', 'or', 'CC', 'I-NP', 'O')
('hearing', 'hearing', 'NN', 'I-NP', 'O')
('loss', 'loss', 'NN', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('full', 'full', 'JJ', 'I-NP', 'O')
('or', 'or', 'CC', 'I-NP', 'O')
('partial', 'partial', 'JJ', 'I-NP', 'O')
('decrease', 'decrease', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('ability', 'ability', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('perceive', 'perceive', 'VB', 'I-VP', 'O')
('sounds,', 'sounds,', 'NN', 'B-NP', 'O')
('induced', 'induce', 'VBN', 'B-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('various', 'various', 'JJ', 'B-NP', 'O')
('biological', 'biological', 'JJ', 'I-NP', 'O')
('(Tremblay', '(Tremblay', 'NNP', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('Ross,', 'Ross,', 'NNP', 'I-NP', 'O')
('2007),', '2007),', 'VBD', 'B-VP', 'O')
('environmental', 'environmental', 'JJ', 'B-NP', 'O')
('(Eyken', '(Eyken', 'NNP', 'I-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'VBD', 'B-VP', 'O')
('2007),', '2007),', 'CD', 'B-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('genetic', 'genetic', 'JJ', 'B-NP', 'O')
('factors.', 'factors.', 'NNS', 'I-NP', 'O')
Various dominant and recessive genes subsist that induce inherited hearing impairments (Laer et al., 2001).
('Various', 'Various', 'JJ', 'B-NP', 'O')
('dominant', 'dominant', 'JJ', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('recessive', 'recessive', 'JJ', 'I-NP', 'O')
('genes', 'gene', 'NNS', 'I-NP', 'O')
('subsist', 'subsist', 'NN', 'I-NP', 'O')
('that', 'that', 'WDT', 'B-NP', 'O')
('induce', 'induce', 'VBP', 'B-VP', 'O')
('inherited', 'inherit', 'VBN', 'I-VP', 'O')
('hearing', 'hearing', 'NN', 'B-NP', 'O')
('impairments', 'impairment', 'NNS', 'I-NP', 'O')
('(Laer', '(Laer', 'NNP', 'I-NP', 'O')
('et', 'et', 'NN', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2001).', '2001).', 'CD', 'B-NP', 'O')
Kelsell et al.
('Kelsell', 'Kelsell', 'NNP', 'B-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al.', 'al.', 'FW', 'I-NP', 'O')
1997 reported a GJB2 mutation, leading to hearing deterioration.
('1997', '1997', 'CD', 'B-NP', 'O')
('reported', 'report', 'VBD', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('GJB2', 'GJB2', 'NN', 'I-NP', 'B-protein')
('mutation,', 'mutation,', 'NN', 'I-NP', 'O')
('leading', 'lead', 'VBG', 'B-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('hearing', 'hearing', 'NN', 'B-NP', 'O')
('deterioration.', 'deterioration.', 'NN', 'I-NP', 'O')
The gap junction β2 gene (GJB2) is situated on the long arm (q arm) of human chromosome 13 at a position between 11 and 12 (Castillo et al., 2005).
('The', 'The', 'DT', 'B-NP', 'O')
('gap', 'gap', 'NN', 'I-NP', 'B-DNA')
('junction', 'junction', 'NN', 'I-NP', 'I-DNA')
('β2', 'β2', 'CD', 'I-NP', 'I-DNA')
('gene', 'gene', 'NN', 'I-NP', 'I-DNA')
('(GJB2)', '(GJB2)', 'NN', 'I-NP', 'B-protein')
('is', 'be', 'VBZ', 'B-VP', 'O')
('situated', 'situate', 'VBN', 'I-VP', 'O')
('on', 'on', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('long', 'long', 'JJ', 'I-NP', 'O')
('arm', 'arm', 'NN', 'I-NP', 'O')
('(q', '(q', 'NN', 'I-NP', 'O')
('arm)', 'arm)', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('human', 'human', 'JJ', 'B-NP', 'B-DNA')
('chromosome', 'chromosome', 'NN', 'I-NP', 'I-DNA')
('13', '13', 'CD', 'I-NP', 'I-DNA')
('at', 'at', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('position', 'position', 'NN', 'I-NP', 'O')
('between', 'between', 'IN', 'B-PP', 'O')
('11', '11', 'CD', 'B-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('12', '12', 'CD', 'I-NP', 'O')
('(Castillo', '(Castillo', 'NNP', 'I-NP', 'O')
('et', 'et', 'NN', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2005).', '2005).', 'CD', 'B-NP', 'O')
The GJB2 gene encodes for the connexin protein (GJB2 protein) (Cx26) (Latting et al., 2008).
('The', 'The', 'DT', 'B-NP', 'O')
('GJB2', 'GJB2', 'NN', 'I-NP', 'B-DNA')
('gene', 'gene', 'NN', 'I-NP', 'I-DNA')
('encodes', 'encode', 'VBZ', 'B-VP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('connexin', 'connexin', 'NN', 'I-NP', 'O')
('protein', 'protein', 'NN', 'I-NP', 'O')
('(GJB2', '(GJB2', 'NN', 'I-NP', 'O')
('protein)', 'protein)', 'NN', 'I-NP', 'O')
('(Cx26)', '(Cx26)', 'NN', 'I-NP', 'O')
('(Latting', '(Latte', 'VBG', 'B-VP', 'O')
('et', 'et', 'NN', 'B-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2008).', '2008).', 'CD', 'B-NP', 'O')
Gap junction β2 protein, commonly known as connexin 26 (Cx26), belongs to a family of structurally related transmembrane proteins that mediate intracellular transport of various ions and molecules (Sosinsky, 1995).
('Gap', 'Gap', 'NN', 'B-NP', 'B-protein')
('junction', 'junction', 'NN', 'I-NP', 'O')
('β2', 'β2', 'CD', 'I-NP', 'O')
('protein,', 'protein,', 'NN', 'I-NP', 'O')
('commonly', 'commonly', 'RB', 'B-VP', 'O')
('known', 'know', 'VBN', 'I-VP', 'O')
('as', 'as', 'IN', 'B-PP', 'O')
('connexin', 'connexin', 'NN', 'B-NP', 'O')
('26', '26', 'CD', 'I-NP', 'O')
('(Cx26),', '(Cx26),', 'NN', 'I-NP', 'B-protein')
('belongs', 'belong', 'VBZ', 'B-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('family', 'family', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('structurally', 'structurally', 'RB', 'B-NP', 'O')
('related', 'related', 'JJ', 'I-NP', 'O')
('transmembrane', 'transmembrane', 'NN', 'I-NP', 'B-protein')
('proteins', 'protein', 'NNS', 'I-NP', 'I-protein')
('that', 'that', 'WDT', 'B-NP', 'O')
('mediate', 'mediate', 'VBP', 'B-VP', 'O')
('intracellular', 'intracellular', 'JJ', 'B-NP', 'O')
('transport', 'transport', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('various', 'various', 'JJ', 'B-NP', 'O')
('ions', 'ion', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('molecules', 'molecule', 'NNS', 'I-NP', 'O')
('(Sosinsky,', '(Sosinsky,', 'NN', 'I-NP', 'B-protein')
('1995).', '1995).', 'CD', 'I-NP', 'I-protein')
Various connexin proteins assemble with each other and form gap junctions.
('Various', 'Various', 'JJ', 'B-NP', 'O')
('connexin', 'connexin', 'NN', 'I-NP', 'O')
('proteins', 'protein', 'NNS', 'I-NP', 'O')
('assemble', 'assemble', 'VBP', 'B-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('each', 'each', 'DT', 'B-NP', 'O')
('other', 'other', 'JJ', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('form', 'form', 'NN', 'I-NP', 'O')
('gap', 'gap', 'NN', 'I-NP', 'O')
('junctions.', 'junctions.', 'NNS', 'I-NP', 'O')
Gap junctions are the clusters of intercellular channels involved in direct communication between cells.
('Gap', 'Gap', 'NN', 'B-NP', 'B-protein')
('junctions', 'junction', 'NNS', 'I-NP', 'O')
('are', 'be', 'VBP', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('clusters', 'cluster', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('intercellular', 'intercellular', 'JJ', 'B-NP', 'B-protein')
('channels', 'channel', 'NNS', 'I-NP', 'I-protein')
('involved', 'involve', 'VBN', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('direct', 'direct', 'JJ', 'B-NP', 'O')
('communication', 'communication', 'NN', 'I-NP', 'O')
('between', 'between', 'IN', 'B-PP', 'O')
('cells.', 'cells.', 'NNS', 'B-NP', 'O')
GJB2 mutations result in altered protein sequences.
('GJB2', 'GJB2', 'NN', 'B-NP', 'B-protein')
('mutations', 'mutation', 'NNS', 'I-NP', 'O')
('result', 'result', 'VBP', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('altered', 'alter', 'VBN', 'B-NP', 'O')
('protein', 'protein', 'NN', 'I-NP', 'O')
('sequences.', 'sequences.', 'NNS', 'I-NP', 'O')
Alterations in the protein sequence are the predominant cause of inherited, sensorineural deafness (Zelante et al., 1997).
('Alterations', 'Alteration', 'NNS', 'B-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('protein', 'protein', 'NN', 'I-NP', 'B-DNA')
('sequence', 'sequence', 'NN', 'I-NP', 'I-DNA')
('are', 'be', 'VBP', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('predominant', 'predominant', 'JJ', 'I-NP', 'O')
('cause', 'cause', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('inherited,', 'inherited,', 'NN', 'B-NP', 'O')
('sensorineural', 'sensorineural', 'JJ', 'I-NP', 'O')
('deafness', 'deafness', 'NN', 'I-NP', 'O')
('(Zelante', '(Zelante', 'NNP', 'I-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('1997).', '1997).', 'CD', 'B-NP', 'O')
Immunohistochemistry of inner ear tissues has shown that connexin 26 and connexin 30 colocalize (Forge et al., 2002; Lautermann et al., 1998).
('Immunohistochemistry', 'Immunohistochemistry', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('inner', 'inner', 'JJ', 'B-NP', 'O')
('ear', 'ear', 'JJ', 'I-NP', 'O')
('tissues', 'tissue', 'NNS', 'I-NP', 'O')
('has', 'have', 'VBZ', 'B-VP', 'O')
('shown', 'show', 'VBN', 'I-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('connexin', 'connexin', 'NN', 'B-NP', 'O')
('26', '26', 'CD', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('connexin', 'connexin', 'NN', 'B-NP', 'O')
('30', '30', 'CD', 'I-NP', 'O')
('colocalize', 'colocalize', 'VBP', 'B-VP', 'O')
('(Forge', '(Forge', 'NNP', 'B-NP', 'B-protein')
('et', 'et', 'NNP', 'I-NP', 'I-protein')
('al.,', 'al.,', 'VBD', 'B-VP', 'I-protein')
('2002;', '2002;', ':', 'O', 'I-protein')
('Lautermann', 'Lautermann', 'NNP', 'B-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('1998).', '1998).', 'CD', 'B-NP', 'O')
Connexin 26 has a structural resemblance to innexins that form gap junctions in invertebrates but has quite a different protein sequence.
('Connexin', 'Connexin', 'NN', 'B-NP', 'O')
('26', '26', 'CD', 'I-NP', 'O')
('has', 'have', 'VBZ', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('structural', 'structural', 'JJ', 'I-NP', 'O')
('resemblance', 'resemblance', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('innexins', 'innexin', 'NNS', 'B-NP', 'O')
('that', 'that', 'WDT', 'B-NP', 'O')
('form', 'form', 'VBP', 'B-VP', 'O')
('gap', 'gap', 'NN', 'B-NP', 'O')
('junctions', 'junction', 'NNS', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('invertebrates', 'invertebrate', 'NNS', 'B-NP', 'O')
('but', 'but', 'CC', 'O', 'O')
('has', 'have', 'VBZ', 'B-VP', 'O')
('quite', 'quite', 'RB', 'B-NP', 'O')
('a', 'a', 'DT', 'I-NP', 'O')
('different', 'different', 'JJ', 'I-NP', 'O')
('protein', 'protein', 'NN', 'I-NP', 'O')
('sequence.', 'sequence.', 'NN', 'I-NP', 'O')
The molecular weight of connexin is about 26 KDa, a product of the GJB2 gene.
('The', 'The', 'DT', 'B-NP', 'O')
('molecular', 'molecular', 'JJ', 'I-NP', 'O')
('weight', 'weight', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('connexin', 'connexin', 'NN', 'B-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('about', 'about', 'RB', 'B-NP', 'O')
('26', '26', 'CD', 'I-NP', 'O')
('KDa,', 'KDa,', 'NN', 'I-NP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('product', 'product', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('GJB2', 'GJB2', 'NN', 'I-NP', 'B-protein')
('gene.', 'gene.', 'NN', 'I-NP', 'O')
Connexin exists in a dynamic cycle of synthesis and replacement because of a short life span of a few hours (Musil, et al., 1993).
('Connexin', 'Connexin', 'NNP', 'B-NP', 'O')
('exists', 'exist', 'VBZ', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('dynamic', 'dynamic', 'JJ', 'I-NP', 'O')
('cycle', 'cycle', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('synthesis', 'synthesis', 'NN', 'B-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('replacement', 'replacement', 'NN', 'I-NP', 'O')
('because', 'because', 'IN', 'B-PP', 'O')
('of', 'of', 'IN', 'I-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('short', 'short', 'JJ', 'I-NP', 'O')
('life', 'life', 'NN', 'I-NP', 'O')
('span', 'span', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('few', 'few', 'JJ', 'I-NP', 'O')
('hours', 'hour', 'NNS', 'I-NP', 'O')
('(Musil,', '(Musil,', 'NNP', 'I-NP', 'O')
('et', 'et', 'NN', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('1993).', '1993).', 'CD', 'B-NP', 'O')
Connexin 26 is found in cells throughout the body, particularly in the inner ear and the skin, and permits the transport of potassium ions and small molecules in neighboring cells (Castillo et al., 2005).
('Connexin', 'Connexin', 'NN', 'B-NP', 'O')
('26', '26', 'CD', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('found', 'find', 'VBN', 'I-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('cells', 'cell', 'NNS', 'B-NP', 'O')
('throughout', 'throughout', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('body,', 'body,', 'NN', 'I-NP', 'O')
('particularly', 'particularly', 'RB', 'B-ADVP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('inner', 'inner', 'JJ', 'I-NP', 'O')
('ear', 'ear', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('skin,', 'skin,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('permits', 'permit', 'VBZ', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('transport', 'transport', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('potassium', 'potassium', 'NN', 'B-NP', 'O')
('ions', 'ion', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('small', 'small', 'JJ', 'B-NP', 'O')
('molecules', 'molecule', 'NNS', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('neighboring', 'neighbor', 'VBG', 'B-NP', 'O')
('cells', 'cell', 'NNS', 'I-NP', 'O')
('(Castillo', '(Castillo', 'NNP', 'B-NP', 'O')
('et', 'et', 'NN', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2005).', '2005).', 'CD', 'B-NP', 'O')
Its presence in the cochlea is associated with hearing.
('Its', 'Its', 'PRP$', 'B-NP', 'O')
('presence', 'presence', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('cochlea', 'cochlea', 'NN', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('associated', 'associate', 'VBN', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('hearing.', 'hearing.', 'NN', 'B-NP', 'O')
GJB2 mutations are the cause of recessive and dominant forms of deafness (Laer et al., 2001), affecting 1 in 1000 children (BitnerGlindzicz, 2002).
('GJB2', 'GJB2', 'NN', 'B-NP', 'B-protein')
('mutations', 'mutation', 'NNS', 'I-NP', 'O')
('are', 'be', 'VBP', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('cause', 'cause', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('recessive', 'recessive', 'JJ', 'B-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('dominant', 'dominant', 'JJ', 'I-NP', 'O')
('forms', 'form', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('deafness', 'deafness', 'NN', 'B-NP', 'B-protein')
('(Laer', '(Laer', 'NNP', 'I-NP', 'I-protein')
('et', 'et', 'FW', 'I-NP', 'I-protein')
('al.,', 'al.,', 'FW', 'I-NP', 'I-protein')
('2001),', '2001),', 'CD', 'I-NP', 'I-protein')
('affecting', 'affect', 'VBG', 'B-VP', 'I-protein')
('1', '1', 'CD', 'B-NP', 'I-protein')
('in', 'in', 'IN', 'B-PP', 'O')
('1000', '1000', 'CD', 'B-NP', 'O')
('children', 'child', 'NNS', 'I-NP', 'O')
('(BitnerGlindzicz,', '(BitnerGlindzicz,', 'IN', 'B-PP', 'O')
('2002).', '2002).', 'CD', 'B-NP', 'O')
About 20 mutations of gap junction β2 have been described as being related to diseases (Abe et al., 2000) and various syndromes, such as BartPumphrey Syndrome, Keratitis IchthyosisDeafness Syndrome, and Vohwinkel Syndrome.
('About', 'About', 'IN', 'B-NP', 'O')
('20', '20', 'CD', 'I-NP', 'O')
('mutations', 'mutation', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('gap', 'gap', 'NN', 'B-NP', 'B-protein')
('junction', 'junction', 'NN', 'I-NP', 'I-protein')
('β2', 'β2', 'NN', 'I-NP', 'I-protein')
('have', 'have', 'VBP', 'B-VP', 'O')
('been', 'be', 'VBN', 'I-VP', 'O')
('described', 'describe', 'VBN', 'I-VP', 'O')
('as', 'as', 'IN', 'B-PP', 'O')
('being', 'be', 'VBG', 'B-VP', 'O')
('related', 'relate', 'VBN', 'I-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('diseases', 'disease', 'NNS', 'B-NP', 'O')
('(Abe', '(Abe', 'NNP', 'B-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al.,', 'al.,', 'FW', 'I-NP', 'O')
('2000)', '2000)', 'CD', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('various', 'various', 'JJ', 'B-NP', 'O')
('syndromes,', 'syndromes,', 'NN', 'I-NP', 'O')
('such', 'such', 'JJ', 'B-PP', 'O')
('as', 'as', 'IN', 'I-PP', 'O')
('BartPumphrey', 'BartPumphrey', 'NNP', 'B-NP', 'O')
('Syndrome,', 'Syndrome,', 'NNP', 'I-NP', 'O')
('Keratitis', 'Keratitis', 'NNP', 'I-NP', 'O')
('IchthyosisDeafness', 'IchthyosisDeafness', 'NNP', 'I-NP', 'O')
('Syndrome,', 'Syndrome,', 'NNP', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('Vohwinkel', 'Vohwinkel', 'NNP', 'B-NP', 'O')
('Syndrome.', 'Syndrome.', 'NNP', 'I-NP', 'O')
(Richard et al., 2004; Snoeckx et al., 2005; Yotsumoto et al., 2003).
('(Richard', '(Richard', 'NNP', 'B-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'VBD', 'B-VP', 'O')
('2004;', '2004;', ':', 'O', 'O')
('Snoeckx', 'Snoeckx', 'NNP', 'B-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al.,', 'al.,', 'FW', 'I-NP', 'O')
('2005;', '2005;', ':', 'O', 'O')
('Yotsumoto', 'Yotsumoto', 'NNP', 'B-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2003).', '2003).', 'CD', 'B-NP', 'O')
The mutations alter the amino acid sequence of connexin 26 and result in impaired functioning of the protein associated with ion channels, especially.
('The', 'The', 'DT', 'B-NP', 'O')
('mutations', 'mutation', 'NNS', 'I-NP', 'O')
('alter', 'alter', 'VBP', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('amino', 'amino', 'JJ', 'I-NP', 'B-protein')
('acid', 'acid', 'NN', 'I-NP', 'I-protein')
('sequence', 'sequence', 'NN', 'I-NP', 'I-protein')
('of', 'of', 'IN', 'B-PP', 'O')
('connexin', 'connexin', 'NN', 'B-NP', 'O')
('26', '26', 'CD', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('result', 'result', 'VBP', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('impaired', 'impaired', 'JJ', 'B-NP', 'O')
('functioning', 'functioning', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('protein', 'protein', 'NN', 'I-NP', 'O')
('associated', 'associate', 'VBN', 'B-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('ion', 'ion', 'NN', 'B-NP', 'O')
('channels,', 'channels,', 'NN', 'I-NP', 'O')
('especially.', 'especially.', 'NN', 'I-NP', 'O')
In fact, a range of phenotypic presentations of autosomal dominant and recessive gap junction β2 gene mutations are intriguing.
('In', 'In', 'IN', 'B-PP', 'O')
('fact,', 'fact,', 'NN', 'B-NP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('range', 'range', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('phenotypic', 'phenotypic', 'JJ', 'B-NP', 'O')
('presentations', 'presentation', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('autosomal', 'autosomal', 'JJ', 'B-NP', 'O')
('dominant', 'dominant', 'JJ', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('recessive', 'recessive', 'JJ', 'I-NP', 'O')
('gap', 'gap', 'NN', 'I-NP', 'O')
('junction', 'junction', 'NN', 'I-NP', 'O')
('β2', 'β2', 'NN', 'I-NP', 'O')
('gene', 'gene', 'NN', 'I-NP', 'O')
('mutations', 'mutation', 'NNS', 'I-NP', 'O')
('are', 'be', 'VBP', 'B-VP', 'O')
('intriguing.', 'intriguing.', 'JJ', 'B-ADJP', 'O')
Such mutations result in an unstable or malformed protein, unable to form gap junctions, or they result in a modified protein that builds dysfunctional gap junctions.
('Such', 'Such', 'JJ', 'B-NP', 'O')
('mutations', 'mutation', 'NNS', 'I-NP', 'O')
('result', 'result', 'VBP', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('unstable', 'unstable', 'JJ', 'I-NP', 'O')
('or', 'or', 'CC', 'I-NP', 'O')
('malformed', 'malforme', 'VBN', 'I-NP', 'O')
('protein,', 'protein,', 'NN', 'I-NP', 'O')
('unable', 'unable', 'JJ', 'B-ADJP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('form', 'form', 'VB', 'I-VP', 'O')
('gap', 'gap', 'NN', 'B-NP', 'O')
('junctions,', 'junctions,', 'NN', 'I-NP', 'O')
('or', 'or', 'CC', 'O', 'O')
('they', 'they', 'PRP', 'B-NP', 'O')
('result', 'result', 'VBP', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('modified', 'modify', 'VBN', 'I-NP', 'B-protein')
('protein', 'protein', 'NN', 'I-NP', 'I-protein')
('that', 'that', 'WDT', 'B-NP', 'O')
('builds', 'build', 'VBZ', 'B-VP', 'O')
('dysfunctional', 'dysfunctional', 'JJ', 'B-NP', 'O')
('gap', 'gap', 'NN', 'I-NP', 'O')
('junctions.', 'junctions.', 'NNS', 'I-NP', 'O')
So, the falsified or modified connexin 26 curbs the normal arrangement of gap junctions and, hence, their proper functioning, affecting the transition of sound waves to neural impulses.
('So,', 'So,', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('falsified', 'falsify', 'VBN', 'I-NP', 'O')
('or', 'or', 'CC', 'I-NP', 'O')
('modified', 'modify', 'VBN', 'I-NP', 'O')
('connexin', 'connexin', 'NN', 'I-NP', 'O')
('26', '26', 'CD', 'B-NP', 'O')
('curbs', 'curb', 'NNS', 'I-NP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('normal', 'normal', 'JJ', 'I-NP', 'O')
('arrangement', 'arrangement', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('gap', 'gap', 'NN', 'B-NP', 'O')
('junctions', 'junction', 'NNS', 'I-NP', 'O')
('and,', 'and,', 'CC', 'O', 'O')
('hence,', 'hence,', 'RB', 'B-ADVP', 'O')
('their', 'their', 'PRP$', 'B-NP', 'O')
('proper', 'proper', 'JJ', 'I-NP', 'O')
('functioning,', 'functioning,', 'NN', 'I-NP', 'O')
('affecting', 'affect', 'VBG', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('transition', 'transition', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('sound', 'sound', 'JJ', 'B-NP', 'O')
('waves', 'wave', 'NNS', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('neural', 'neural', 'JJ', 'B-NP', 'O')
('impulses.', 'impulses.', 'NNS', 'I-NP', 'O')
So, the present study was carried out to highlight the structural changes, especially the hydrogen bonding, bond angles, bond length, force field energies, and PI values, because such forces and factors are considered to be contributing to the effect on amino acid residues, their stability, and normal functioning (Karaguller et al., 2004; Talley et al., 2008).
('So,', 'So,', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('present', 'present', 'JJ', 'I-NP', 'O')
('study', 'study', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('carried', 'carry', 'VBN', 'I-VP', 'O')
('out', 'out', 'RP', 'B-PRT', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('highlight', 'highlight', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('structural', 'structural', 'JJ', 'I-NP', 'O')
('changes,', 'changes,', 'NN', 'I-NP', 'O')
('especially', 'especially', 'RB', 'B-ADVP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('hydrogen', 'hydrogen', 'NN', 'I-NP', 'O')
('bonding,', 'bonding,', 'NN', 'I-NP', 'O')
('bond', 'bond', 'NN', 'I-NP', 'O')
('angles,', 'angles,', 'NN', 'I-NP', 'O')
('bond', 'bond', 'NN', 'I-NP', 'O')
('length,', 'length,', 'NN', 'I-NP', 'O')
('force', 'force', 'NN', 'I-NP', 'O')
('field', 'field', 'NN', 'I-NP', 'O')
('energies,', 'energies,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('PI', 'PI', 'NN', 'B-NP', 'O')
('values,', 'values,', 'NN', 'I-NP', 'O')
('because', 'because', 'IN', 'B-SBAR', 'O')
('such', 'such', 'JJ', 'B-NP', 'O')
('forces', 'force', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('factors', 'factor', 'NNS', 'I-NP', 'O')
('are', 'be', 'VBP', 'B-VP', 'O')
('considered', 'consider', 'VBN', 'I-VP', 'O')
('to', 'to', 'TO', 'I-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('contributing', 'contribute', 'VBG', 'I-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('effect', 'effect', 'NN', 'I-NP', 'O')
('on', 'on', 'IN', 'B-PP', 'O')
('amino', 'amino', 'NN', 'B-NP', 'O')
('acid', 'acid', 'NN', 'I-NP', 'O')
('residues,', 'residues,', 'VBD', 'B-VP', 'O')
('their', 'their', 'PRP$', 'B-NP', 'O')
('stability,', 'stability,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('normal', 'normal', 'JJ', 'I-NP', 'O')
('functioning', 'function', 'VBG', 'I-NP', 'O')
('(Karaguller', '(Karaguller', 'NNP', 'I-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'VBD', 'B-VP', 'O')
('2004;', '2004;', ':', 'O', 'O')
('Talley', 'Talley', 'NNP', 'B-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2008).', '2008).', 'CD', 'B-NP', 'O')
βThe X-ray crystallographic structure of connexin 26 is not known.
('βThe', 'βThe', 'DT', 'B-NP', 'O')
('X-ray', 'X-ray', 'JJ', 'I-NP', 'O')
('crystallographic', 'crystallographic', 'JJ', 'I-NP', 'O')
('structure', 'structure', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('connexin', 'connexin', 'NN', 'B-NP', 'O')
('26', '26', 'CD', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('not', 'not', 'RB', 'I-VP', 'O')
('known.', 'known.', 'VB', 'I-VP', 'O')
But, the protein sequence and basic protein structure are known and well characterized (Fig.
('But,', 'But,', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('protein', 'protein', 'NN', 'I-NP', 'O')
('sequence', 'sequence', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('basic', 'basic', 'JJ', 'B-NP', 'O')
('protein', 'protein', 'NN', 'I-NP', 'O')
('structure', 'structure', 'NN', 'I-NP', 'O')
('are', 'be', 'VBP', 'B-VP', 'O')
('known', 'know', 'VBN', 'I-VP', 'O')
('and', 'and', 'CC', 'O', 'O')
('well', 'well', 'RB', 'B-VP', 'O')
('characterized', 'characterize', 'VBN', 'I-VP', 'O')
('(Fig.', '(Fig.', 'NNP', 'B-NP', 'O')
1).
('1).', '1).', 'LS', 'B-LST', 'O')
Sequence Analysis: The primary sequence of human connexin 26 (primary accession no.
('Sequence', 'Sequence', 'NN', 'B-NP', 'O')
('Analysis:', 'Analysis:', ':', 'O', 'O')
('The', 'The', 'DT', 'B-NP', 'O')
('primary', 'primary', 'JJ', 'I-NP', 'B-DNA')
('sequence', 'sequence', 'NN', 'I-NP', 'I-DNA')
('of', 'of', 'IN', 'B-PP', 'O')
('human', 'human', 'JJ', 'B-NP', 'O')
('connexin', 'connexin', 'NN', 'I-NP', 'O')
('26', '26', 'CD', 'I-NP', 'O')
('(primary', '(primary', 'JJ', 'I-NP', 'O')
('accession', 'accession', 'NN', 'I-NP', 'O')
('no.', 'no.', 'NN', 'I-NP', 'O')
P29033) was retrieved from SWISS-Prot (Bairoch and Apweiler, 1997).
('P29033)', 'P29033)', 'NN', 'B-NP', 'B-protein')
('was', 'be', 'VBD', 'B-VP', 'O')
('retrieved', 'retrieve', 'VBN', 'I-VP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('SWISS-Prot', 'SWISS-Prot', 'NNP', 'B-NP', 'O')
('(Bairoch', '(Bairoch', 'NNP', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('Apweiler,', 'Apweiler,', 'NNP', 'B-NP', 'O')
('1997).', '1997).', 'CD', 'I-NP', 'O')
Using in silico tools, a theoretically designed homology model (1xir) was obtained from Protein Data Bank (PDB).
('Using', 'Use', 'VBG', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('silico', 'silico', 'NN', 'B-NP', 'O')
('tools,', 'tools,', 'VBD', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('theoretically', 'theoretically', 'RB', 'I-NP', 'O')
('designed', 'design', 'VBN', 'I-NP', 'O')
('homology', 'homology', 'NN', 'I-NP', 'O')
('model', 'model', 'NN', 'I-NP', 'O')
('(1xir)', '(1xir)', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('obtained', 'obtain', 'VBN', 'I-VP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('Protein', 'Protein', 'NNP', 'B-NP', 'O')
('Data', 'Data', 'NNP', 'I-NP', 'O')
('Bank', 'Bank', 'NNP', 'I-NP', 'O')
('(PDB).', '(PDB).', 'NNP', 'I-NP', 'O')
Homology modeling can be described in four steps: (A) identification of a homolog from PDB whose structure is known; (B) alignment/positioning of our query sequence to the template or model sequence; (C) construction of the replica/model based on the alignment; and (D) entrance and refinement of the model.
('Homology', 'Homology', 'NN', 'B-NP', 'O')
('modeling', 'modeling', 'NN', 'I-NP', 'O')
('can', 'can', 'MD', 'B-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('described', 'describe', 'VBN', 'I-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('four', 'four', 'CD', 'B-NP', 'O')
('steps:', 'steps:', 'SYM', 'I-NP', 'O')
('(A)', '(A)', 'NN', 'I-NP', 'O')
('identification', 'identification', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('homolog', 'homolog', 'NN', 'I-NP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('PDB', 'PDB', 'NN', 'B-NP', 'B-protein')
('whose', 'whose', 'WP$', 'B-NP', 'O')
('structure', 'structure', 'NN', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('known;', 'known;', 'JJ', 'B-NP', 'O')
('(B)', '(B)', 'NN', 'I-NP', 'O')
('alignment/positioning', 'alignment/positioning', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('our', 'our', 'PRP$', 'B-NP', 'O')
('query', 'query', 'NN', 'I-NP', 'B-DNA')
('sequence', 'sequence', 'NN', 'I-NP', 'I-DNA')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('template', 'template', 'NN', 'I-NP', 'O')
('or', 'or', 'CC', 'I-NP', 'O')
('model', 'model', 'NN', 'I-NP', 'O')
('sequence;', 'sequence;', 'NN', 'I-NP', 'O')
('(C)', '(C)', 'NN', 'I-NP', 'O')
('construction', 'construction', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('replica/model', 'replica/model', 'NN', 'I-NP', 'O')
('based', 'base', 'VBN', 'B-PP', 'O')
('on', 'on', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('alignment;', 'alignment;', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('(D)', '(D)', 'NN', 'I-NP', 'O')
('entrance', 'entrance', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('refinement', 'refinement', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('model.', 'model.', 'NN', 'I-NP', 'O')
A sequence similarity of 30% to a known protein structure being often predicted and is equivalent to a lowresolution Xray structure (Xiang, 2006).
('A', 'A', 'DT', 'B-NP', 'O')
('sequence', 'sequence', 'NN', 'I-NP', 'O')
('similarity', 'similarity', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('30%', '30%', 'CD', 'B-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('known', 'known', 'JJ', 'I-NP', 'O')
('protein', 'protein', 'NN', 'I-NP', 'O')
('structure', 'structure', 'NN', 'I-NP', 'O')
('being', 'be', 'VBG', 'B-VP', 'O')
('often', 'often', 'RB', 'I-VP', 'O')
('predicted', 'predict', 'VBN', 'I-VP', 'O')
('and', 'and', 'CC', 'O', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('equivalent', 'equivalent', 'JJ', 'B-ADJP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('lowresolution', 'lowresolution', 'NN', 'I-NP', 'O')
('Xray', 'Xray', 'NNP', 'I-NP', 'O')
('structure', 'structure', 'NN', 'I-NP', 'O')
('(Xiang,', '(Xiang,', 'NNP', 'B-NP', 'O')
('2006).', '2006).', 'CD', 'I-NP', 'O')
The 3D coordinates of the template used were available.
('The', 'The', 'DT', 'B-NP', 'O')
('3D', '3D', 'NN', 'I-NP', 'O')
('coordinates', 'coordinate', 'VBZ', 'B-VP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('template', 'template', 'NN', 'I-NP', 'O')
('used', 'use', 'VBN', 'B-VP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('available.', 'available.', 'JJ', 'B-ADJP', 'O')
By using Swiss Protein Deep Viewer, various structural implementations were carried out from the coordinate file for the selected amino acidsAsp66His, Asn54Lys, and Asp50Asninvolved in obvious clinical syndromes (Fig.
('By', 'By', 'IN', 'B-PP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('Swiss', 'Swiss', 'JJ', 'B-NP', 'O')
('Protein', 'Protein', 'NN', 'I-NP', 'O')
('Deep', 'Deep', 'NN', 'I-NP', 'O')
('Viewer,', 'Viewer,', 'NN', 'I-NP', 'O')
('various', 'various', 'JJ', 'I-NP', 'O')
('structural', 'structural', 'JJ', 'I-NP', 'O')
('implementations', 'implementation', 'NNS', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('carried', 'carry', 'VBN', 'I-VP', 'O')
('out', 'out', 'RP', 'B-PRT', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('coordinate', 'coordinate', 'JJ', 'I-NP', 'O')
('file', 'file', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('selected', 'select', 'VBN', 'I-NP', 'O')
('amino', 'amino', 'NN', 'I-NP', 'B-protein')
('acidsAsp66His,', 'acidsAsp66His,', 'NN', 'I-NP', 'I-protein')
('Asn54Lys,', 'Asn54Lys,', 'NN', 'I-NP', 'I-protein')
('and', 'and', 'CC', 'O', 'O')
('Asp50Asninvolved', 'Asp50Asninvolve', 'VBN', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('obvious', 'obvious', 'JJ', 'B-NP', 'O')
('clinical', 'clinical', 'JJ', 'I-NP', 'O')
('syndromes', 'syndrome', 'NNS', 'I-NP', 'O')
('(Fig.', '(Fig.', 'NNP', 'B-NP', 'O')
1).
('1).', '1).', 'LS', 'B-LST', 'O')
Asp66, Asn54, and Asp50 were mutated to His66, Asn54, and Asp50, respectively, and a study was carried out to observe changes in hydrogen bonds, bond lengths, angles, and rotations.
('Asp66,', 'Asp66,', 'NN', 'B-NP', 'O')
('Asn54,', 'Asn54,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('Asp50', 'Asp50', 'NN', 'I-NP', 'B-protein')
('were', 'be', 'VBD', 'B-VP', 'O')
('mutated', 'mutate', 'VBN', 'I-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('His66,', 'His66,', 'NN', 'B-NP', 'O')
('Asn54,', 'Asn54,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('Asp50,', 'Asp50,', 'NN', 'B-NP', 'O')
('respectively,', 'respectively,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('study', 'study', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('carried', 'carry', 'VBN', 'I-VP', 'O')
('out', 'out', 'RP', 'B-PRT', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('observe', 'observe', 'VB', 'I-VP', 'O')
('changes', 'change', 'NNS', 'B-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('hydrogen', 'hydrogen', 'NN', 'B-NP', 'O')
('bonds,', 'bonds,', 'NN', 'I-NP', 'O')
('bond', 'bond', 'NN', 'I-NP', 'O')
('lengths,', 'lengths,', 'NN', 'I-NP', 'O')
('angles,', 'angles,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('rotations.', 'rotations.', 'NN', 'B-NP', 'O')
Energy calculations for wildtype and mutated amino acids were made by using the GROMOSS96 implementation of the Swiss Protein Deep Viewer.
('Energy', 'Energy', 'NN', 'B-NP', 'O')
('calculations', 'calculation', 'NNS', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('wildtype', 'wildtype', 'NN', 'B-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('mutated', 'mutate', 'VBN', 'B-VP', 'O')
('amino', 'amino', 'JJ', 'B-NP', 'O')
('acids', 'acid', 'NNS', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('made', 'make', 'VBN', 'I-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('GROMOSS96', 'GROMOSS96', 'NN', 'I-NP', 'O')
('implementation', 'implementation', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('Swiss', 'Swiss', 'NNP', 'I-NP', 'O')
('Protein', 'Protein', 'NNP', 'I-NP', 'O')
('Deep', 'Deep', 'NNP', 'I-NP', 'O')
('Viewer.', 'Viewer.', 'NNP', 'I-NP', 'O')
The PI values of the individual amino acid residues, wildtype and mutant, were compared on the basis of an available table (Williams et al., 1987).
('The', 'The', 'DT', 'B-NP', 'O')
('PI', 'PI', 'NN', 'I-NP', 'O')
('values', 'value', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('individual', 'individual', 'JJ', 'I-NP', 'O')
('amino', 'amino', 'NN', 'I-NP', 'O')
('acid', 'acid', 'NN', 'I-NP', 'O')
('residues,', 'residues,', 'NN', 'I-NP', 'O')
('wildtype', 'wildtype', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('mutant,', 'mutant,', 'NN', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('compared', 'compare', 'VBN', 'I-VP', 'O')
('on', 'on', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('basis', 'basis', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('available', 'available', 'JJ', 'I-NP', 'O')
('table', 'table', 'NN', 'I-NP', 'O')
('(Williams', '(Williams', 'NNP', 'I-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('1987).', '1987).', 'CD', 'B-NP', 'O')
In nature, a protein is stabilized by protein folds into one or more specific conformations to perform biological functions.
('In', 'In', 'IN', 'B-PP', 'O')
('nature,', 'nature,', 'NN', 'B-NP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('protein', 'protein', 'NN', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('stabilized', 'stabilize', 'VBN', 'I-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('protein', 'protein', 'NN', 'B-NP', 'O')
('folds', 'fold', 'VBZ', 'B-VP', 'O')
('into', 'into', 'IN', 'B-PP', 'O')
('one', 'one', 'CD', 'B-NP', 'O')
('or', 'or', 'CC', 'I-NP', 'O')
('more', 'more', 'JJR', 'I-NP', 'O')
('specific', 'specific', 'JJ', 'I-NP', 'O')
('conformations', 'conformation', 'NNS', 'I-NP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('perform', 'perform', 'VB', 'I-VP', 'O')
('biological', 'biological', 'JJ', 'B-NP', 'O')
('functions.', 'functions.', 'NNS', 'I-NP', 'O')
The specific conformations are driven by various interactions, such as hydrogen bonding, bond angles, and various forces.
('The', 'The', 'DT', 'B-NP', 'O')
('specific', 'specific', 'JJ', 'I-NP', 'O')
('conformations', 'conformation', 'NNS', 'I-NP', 'O')
('are', 'be', 'VBP', 'B-VP', 'O')
('driven', 'drive', 'VBN', 'I-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('various', 'various', 'JJ', 'B-NP', 'O')
('interactions,', 'interactions,', 'NN', 'I-NP', 'O')
('such', 'such', 'JJ', 'B-PP', 'O')
('as', 'as', 'IN', 'I-PP', 'O')
('hydrogen', 'hydrogen', 'NN', 'B-NP', 'O')
('bonding,', 'bonding,', 'NN', 'I-NP', 'O')
('bond', 'bond', 'NN', 'I-NP', 'O')
('angles,', 'angles,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('various', 'various', 'JJ', 'B-NP', 'O')
('forces.', 'forces.', 'NNS', 'I-NP', 'O')
The 226 amino acids of connexin 26 are known.
('The', 'The', 'DT', 'B-NP', 'O')
('226', '226', 'CD', 'I-NP', 'B-protein')
('amino', 'amino', 'NN', 'I-NP', 'I-protein')
('acids', 'acid', 'NNS', 'I-NP', 'I-protein')
('of', 'of', 'IN', 'B-PP', 'O')
('connexin', 'connexin', 'NN', 'B-NP', 'O')
('26', '26', 'CD', 'I-NP', 'O')
('are', 'be', 'VBP', 'B-VP', 'O')
('known.', 'known.', 'JJ', 'B-ADJP', 'O')
The 3D structure of connexin 26 is well known and was obtained from Protein Data Bank.
('The', 'The', 'DT', 'B-NP', 'O')
('3D', '3D', 'NN', 'I-NP', 'O')
('structure', 'structure', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('connexin', 'connexin', 'NN', 'B-NP', 'O')
('26', '26', 'CD', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('well', 'well', 'RB', 'I-VP', 'O')
('known', 'know', 'VBN', 'I-VP', 'O')
('and', 'and', 'CC', 'O', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('obtained', 'obtain', 'VBN', 'I-VP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('Protein', 'Protein', 'NNP', 'B-NP', 'O')
('Data', 'Data', 'NNP', 'I-NP', 'O')
('Bank.', 'Bank.', 'NNP', 'I-NP', 'O')
Mutations in the gap junction β2 gene cause a substitution of different amino acids of connexin 26 and result in various syndromes.
('Mutations', 'Mutation', 'NNS', 'B-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('gap', 'gap', 'NN', 'I-NP', 'B-DNA')
('junction', 'junction', 'NN', 'I-NP', 'I-DNA')
('β2', 'β2', 'NN', 'I-NP', 'I-DNA')
('gene', 'gene', 'NN', 'I-NP', 'I-DNA')
('cause', 'cause', 'VBP', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('substitution', 'substitution', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('different', 'different', 'JJ', 'B-NP', 'O')
('amino', 'amino', 'NN', 'I-NP', 'O')
('acids', 'acid', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('connexin', 'connexin', 'NN', 'B-NP', 'O')
('26', '26', 'CD', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('result', 'result', 'VBP', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('various', 'various', 'JJ', 'B-NP', 'O')
('syndromes.', 'syndromes.', 'NNS', 'I-NP', 'O')
In the present work, 3 amino acids of the E1 domain of the protein were selected to determine the characteristic changes affecting the physiology of connexin 26 (Fig.
('In', 'In', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('present', 'present', 'JJ', 'I-NP', 'O')
('work,', 'work,', 'NN', 'I-NP', 'O')
('3', '3', 'CD', 'I-NP', 'O')
('amino', 'amino', 'NN', 'I-NP', 'O')
('acids', 'acid', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('E1', 'E1', 'NN', 'I-NP', 'B-protein')
('domain', 'domain', 'NN', 'I-NP', 'I-protein')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('protein', 'protein', 'NN', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('selected', 'select', 'VBN', 'I-VP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('determine', 'determine', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('characteristic', 'characteristic', 'JJ', 'I-NP', 'O')
('changes', 'change', 'NNS', 'I-NP', 'O')
('affecting', 'affect', 'VBG', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('physiology', 'physiology', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('connexin', 'connexin', 'NN', 'B-NP', 'O')
('26', '26', 'CD', 'I-NP', 'O')
('(Fig.', '(Fig.', 'NNP', 'I-NP', 'O')
2).
('2).', '2).', 'LS', 'B-LST', 'O')
Asp66His causes a hydrogen bond breakage to Asn62 (Table 1), resulting in a significant increase in energy for bonds (18.494 KJ/mol for mutant compared to 5.516 KJ/mol for wildtype).
('Asp66His', 'Asp66His', 'NN', 'B-NP', 'O')
('causes', 'cause', 'VBZ', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('hydrogen', 'hydrogen', 'NN', 'I-NP', 'O')
('bond', 'bond', 'NN', 'I-NP', 'O')
('breakage', 'breakage', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('Asn62', 'Asn62', 'NN', 'B-NP', 'B-protein')
('(Table', '(Table', 'JJ', 'I-NP', 'O')
('1),', '1),', 'NN', 'I-NP', 'O')
('resulting', 'result', 'VBG', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('significant', 'significant', 'JJ', 'I-NP', 'O')
('increase', 'increase', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('energy', 'energy', 'NN', 'B-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('bonds', 'bond', 'NNS', 'B-NP', 'O')
('(18.494', '(18.494', 'CD', 'B-NP', 'O')
('KJ/mol', 'KJ/mol', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('mutant', 'mutant', 'JJ', 'B-NP', 'O')
('compared', 'compare', 'VBN', 'B-PP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('5.516', '5.516', 'CD', 'B-NP', 'O')
('KJ/mol', 'KJ/mol', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('wildtype).', 'wildtype).', 'NN', 'B-NP', 'O')
The angular energy increased by 2.457 KJ/mol for His66.
('The', 'The', 'DT', 'B-NP', 'O')
('angular', 'angular', 'JJ', 'I-NP', 'O')
('energy', 'energy', 'NN', 'I-NP', 'O')
('increased', 'increase', 'VBD', 'B-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('2.457', '2.457', 'CD', 'B-NP', 'O')
('KJ/mol', 'KJ/mol', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('His66.', 'His66.', 'NN', 'B-NP', 'B-protein')
The CG1CB1 rotation for His66 changed the CA1CB1CG1 angle from 108.76o for the wildtype to 115.05o for the mutated amino acid (Table 2).
('The', 'The', 'DT', 'B-NP', 'O')
('CG1CB1', 'CG1CB1', 'NN', 'I-NP', 'O')
('rotation', 'rotation', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('His66', 'His66', 'NN', 'B-NP', 'B-protein')
('changed', 'change', 'VBD', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('CA1CB1CG1', 'CA1CB1CG1', 'NN', 'I-NP', 'O')
('angle', 'angle', 'NN', 'I-NP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('108.76o', '108.76o', 'CD', 'B-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('wildtype', 'wildtype', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('115.05o', '115.05o', 'VB', 'I-VP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('mutated', 'mutate', 'VBN', 'I-NP', 'O')
('amino', 'amino', 'NN', 'I-NP', 'O')
('acid', 'acid', 'NN', 'I-NP', 'O')
('(Table', '(Table', 'JJ', 'B-ADJP', 'O')
('2).', '2).', 'CD', 'B-NP', 'O')
The CG1CB1 bond rotation disturbs the existing hydrogen bond (2.67 Å) to Asn62 (Fig.
('The', 'The', 'DT', 'B-NP', 'O')
('CG1CB1', 'CG1CB1', 'NN', 'I-NP', 'O')
('bond', 'bond', 'NN', 'I-NP', 'O')
('rotation', 'rotation', 'NN', 'I-NP', 'O')
('disturbs', 'disturb', 'VBZ', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('existing', 'exist', 'VBG', 'I-NP', 'O')
('hydrogen', 'hydrogen', 'NN', 'I-NP', 'O')
('bond', 'bond', 'NN', 'I-NP', 'O')
('(2.67', '(2.67', 'CD', 'I-NP', 'O')
('Å)', 'Å)', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('Asn62', 'Asn62', 'NNP', 'B-NP', 'O')
('(Fig.', '(Fig.', 'NNP', 'I-NP', 'O')
2A, 2B).
('2A,', '2A,', 'NN', 'B-NP', 'O')
('2B).', '2B).', 'NN', 'I-NP', 'O')
The aromatic ring of His66 reduces the distance to Pro70 (CD1CB1 distance, 4.98 Å for wildtype to CE11CG1 4.06 Å bond length for the mutation).
('The', 'The', 'DT', 'B-NP', 'O')
('aromatic', 'aromatic', 'JJ', 'I-NP', 'O')
('ring', 'ring', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('His66', 'His66', 'NN', 'B-NP', 'B-protein')
('reduces', 'reduce', 'VBZ', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('distance', 'distance', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('Pro70', 'Pro70', 'NN', 'B-NP', 'O')
('(CD1CB1', '(CD1CB1', 'NN', 'I-NP', 'O')
('distance,', 'distance,', 'NN', 'I-NP', 'O')
('4.98', '4.98', 'CD', 'I-NP', 'O')
('Å', 'Å', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('wildtype', 'wildtype', 'NN', 'B-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('CE11CG1', 'CE11CG1', 'NN', 'B-NP', 'O')
('4.06', '4.06', 'CD', 'I-NP', 'O')
('Å', 'Å', 'NN', 'I-NP', 'O')
('bond', 'bond', 'NN', 'I-NP', 'O')
('length', 'length', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('mutation).', 'mutation).', 'NN', 'I-NP', 'O')
Another important change observed is the shift in normal charges of the residue from negative to positive, with the increase in PI   value from 2.77 to 7.59.
('Another', 'Another', 'DT', 'B-NP', 'O')
('important', 'important', 'JJ', 'I-NP', 'O')
('change', 'change', 'NN', 'I-NP', 'O')
('observed', 'observe', 'VBN', 'B-VP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('shift', 'shift', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('normal', 'normal', 'JJ', 'B-NP', 'O')
('charges', 'charge', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('residue', 'residue', 'NN', 'I-NP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('negative', 'negative', 'JJ', 'B-ADJP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('positive,', 'positive,', 'VB', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('increase', 'increase', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('PI', 'PI', 'NN', 'B-NP', 'O')
('value', 'value', 'NN', 'I-NP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('2.77', '2.77', 'CD', 'B-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('7.59.', '7.59.', 'CD', 'B-NP', 'O')
But, the shift in hydrogen bonding is enough to play a considerable role in affecting the normal interaction of protein residues and, ultimately, the overall charge of ion channels and their interactions with ions and metabolites associated with transportation functioning.
('But,', 'But,', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('shift', 'shift', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('hydrogen', 'hydrogen', 'NN', 'B-NP', 'O')
('bonding', 'bonding', 'NN', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('enough', 'enough', 'JJ', 'B-ADJP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('play', 'play', 'VB', 'I-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('considerable', 'considerable', 'JJ', 'I-NP', 'O')
('role', 'role', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('affecting', 'affect', 'VBG', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('normal', 'normal', 'JJ', 'I-NP', 'O')
('interaction', 'interaction', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('protein', 'protein', 'NN', 'B-NP', 'O')
('residues', 'residue', 'NNS', 'I-NP', 'O')
('and,', 'and,', 'CC', 'B-PP', 'O')
('ultimately,', 'ultimately,', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('overall', 'overall', 'JJ', 'I-NP', 'O')
('charge', 'charge', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('ion', 'ion', 'NN', 'B-NP', 'O')
('channels', 'channel', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('their', 'their', 'PRP$', 'B-NP', 'O')
('interactions', 'interaction', 'NNS', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('ions', 'ion', 'NNS', 'B-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('metabolites', 'metabolite', 'NNS', 'I-NP', 'O')
('associated', 'associate', 'VBN', 'B-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('transportation', 'transportation', 'NN', 'B-NP', 'O')
('functioning.', 'functioning.', 'NN', 'I-NP', 'O')
The high-molecular-weight (114) polar amino acid asparagine affects the structure of proteins in a highly specific manner by providing a strong driving force for folding.
('The', 'The', 'DT', 'B-NP', 'O')
('high-molecular-weight', 'high-molecular-weight', 'JJ', 'I-NP', 'O')
('(114)', '(114)', 'NN', 'I-NP', 'O')
('polar', 'polar', 'JJ', 'I-NP', 'O')
('amino', 'amino', 'JJ', 'I-NP', 'O')
('acid', 'acid', 'NN', 'I-NP', 'O')
('asparagine', 'asparagine', 'NN', 'I-NP', 'O')
('affects', 'affect', 'VBZ', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('structure', 'structure', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('proteins', 'protein', 'NNS', 'B-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('highly', 'highly', 'RB', 'I-NP', 'O')
('specific', 'specific', 'JJ', 'I-NP', 'O')
('manner', 'manner', 'NN', 'I-NP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('providing', 'provide', 'VBG', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('strong', 'strong', 'JJ', 'I-NP', 'O')
('driving', 'drive', 'VBG', 'I-NP', 'O')
('force', 'force', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('folding.', 'folding.', 'NN', 'B-NP', 'O')
Moreover, it possesses interesting hydrogen bond properties that resemble the backbone peptides.
('Moreover,', 'Moreover,', 'JJR', 'B-ADVP', 'O')
('it', 'it', 'PRP', 'B-NP', 'O')
('possesses', 'possess', 'VBZ', 'B-VP', 'O')
('interesting', 'interesting', 'JJ', 'B-NP', 'O')
('hydrogen', 'hydrogen', 'NN', 'I-NP', 'O')
('bond', 'bond', 'NN', 'I-NP', 'O')
('properties', 'property', 'NNS', 'I-NP', 'O')
('that', 'that', 'WDT', 'B-NP', 'O')
('resemble', 'resemble', 'VBP', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('backbone', 'backbone', 'NN', 'I-NP', 'O')
('peptides.', 'peptides.', 'NN', 'I-NP', 'O')
A missense mutation, Asn54Lys, causes hydrogen bond breakage to Leu56 (3.12 Å) and Thr55 (3.05 Å) (Fig.
('A', 'A', 'DT', 'B-NP', 'O')
('missense', 'missense', 'JJ', 'I-NP', 'O')
('mutation,', 'mutation,', 'NN', 'I-NP', 'O')
('Asn54Lys,', 'Asn54Lys,', 'NN', 'I-NP', 'O')
('causes', 'cause', 'VBZ', 'B-VP', 'O')
('hydrogen', 'hydrogen', 'NN', 'B-NP', 'O')
('bond', 'bond', 'NN', 'I-NP', 'O')
('breakage', 'breakage', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('Leu56', 'Leu56', 'NN', 'B-NP', 'O')
('(3.12', '(3.12', 'NN', 'I-NP', 'O')
('Å)', 'Å)', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('Thr55', 'Thr55', 'NN', 'B-NP', 'B-protein')
('(3.05', '(3.05', 'CD', 'I-NP', 'I-protein')
('Å)', 'Å)', 'LS', 'O', 'O')
('(Fig.', '(Fig.', 'NNP', 'B-NP', 'O')
2C, 2D).
('2C,', '2C,', 'NN', 'B-NP', 'O')
('2D).', '2D).', 'NN', 'I-NP', 'O')
The hydrogen bond breakage results in a shift in tortional energy (4.702 kJ/mol for wildtype to 7.002 kJ/mol for mutant) and a tremendous decrease in electrostatic potential energy by 37.5 kJ/mol (52.92 kJ/mol for wildtype                                   to 15.42 kJ/mol for the mutation), along with a decrease in energy for bonds (7.729 kJ/mol for wildtype to 5.777 for mutant) and angles (1.841 kJ/mol for wildtype and 1.421 kJ/mol for mutant) (Table 1 & 2).
('The', 'The', 'DT', 'B-NP', 'O')
('hydrogen', 'hydrogen', 'NN', 'I-NP', 'O')
('bond', 'bond', 'NN', 'I-NP', 'O')
('breakage', 'breakage', 'NN', 'I-NP', 'O')
('results', 'result', 'VBZ', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('shift', 'shift', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('tortional', 'tortional', 'JJ', 'B-NP', 'O')
('energy', 'energy', 'NN', 'I-NP', 'O')
('(4.702', '(4.702', 'NN', 'I-NP', 'O')
('kJ/mol', 'kJ/mol', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('wildtype', 'wildtype', 'NN', 'B-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('7.002', '7.002', 'CD', 'B-NP', 'O')
('kJ/mol', 'kJ/mol', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('mutant)', 'mutant)', 'NN', 'B-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('tremendous', 'tremendous', 'JJ', 'I-NP', 'O')
('decrease', 'decrease', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('electrostatic', 'electrostatic', 'JJ', 'B-NP', 'O')
('potential', 'potential', 'JJ', 'I-NP', 'O')
('energy', 'energy', 'NN', 'I-NP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('37.5', '37.5', 'CD', 'B-NP', 'O')
('kJ/mol', 'kJ/mol', 'NN', 'I-NP', 'O')
('(52.92', '(52.92', 'NN', 'I-NP', 'O')
('kJ/mol', 'kJ/mol', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('wildtype', 'wildtype', 'NN', 'B-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('15.42', '15.42', 'CD', 'B-NP', 'O')
('kJ/mol', 'kJ/mol', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('mutation),', 'mutation),', 'NN', 'I-NP', 'O')
('along', 'along', 'IN', 'B-ADVP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('decrease', 'decrease', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('energy', 'energy', 'NN', 'B-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('bonds', 'bond', 'NNS', 'B-NP', 'O')
('(7.729', '(7.729', 'CD', 'B-NP', 'O')
('kJ/mol', 'kJ/mol', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('wildtype', 'wildtype', 'NN', 'B-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('5.777', '5.777', 'CD', 'B-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('mutant)', 'mutant)', 'NN', 'B-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('angles', 'angle', 'VBZ', 'B-VP', 'O')
('(1.841', '(1.841', 'CD', 'B-NP', 'O')
('kJ/mol', 'kJ/mol', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('wildtype', 'wildtype', 'JJ', 'B-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('1.421', '1.421', 'CD', 'I-NP', 'O')
('kJ/mol', 'kJ/mol', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('mutant)', 'mutant)', 'NN', 'B-NP', 'B-protein')
('(Table', '(Table', 'NN', 'I-NP', 'I-protein')
('1', '1', 'CD', 'I-NP', 'I-protein')
('&', '&', 'CC', 'I-NP', 'O')
('2).', '2).', 'CD', 'I-NP', 'O')
The additional methyl groups (CD1 and CE1) of the mutant Lys54 side chain, compared to the wild-type Asn54 residue, results in much closer contact with the adjacent Val84 side chain (2.98 Å for mutant compared to 4.21 Å for wild-type) and forms a new hydrogen bond (2.39 Å) to the carbonyl group of Ser113 (Fig.
('The', 'The', 'DT', 'B-NP', 'O')
('additional', 'additional', 'JJ', 'I-NP', 'O')
('methyl', 'methyl', 'NN', 'I-NP', 'O')
('groups', 'group', 'NNS', 'I-NP', 'O')
('(CD1', '(CD1', 'NN', 'I-NP', 'B-protein')
('and', 'and', 'CC', 'I-NP', 'O')
('CE1)', 'CE1)', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('mutant', 'mutant', 'JJ', 'I-NP', 'O')
('Lys54', 'Lys54', 'NN', 'I-NP', 'O')
('side', 'side', 'NN', 'I-NP', 'O')
('chain,', 'chain,', 'NN', 'I-NP', 'O')
('compared', 'compare', 'VBN', 'B-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('wild-type', 'wild-type', 'JJ', 'I-NP', 'B-protein')
('Asn54', 'Asn54', 'NN', 'I-NP', 'I-protein')
('residue,', 'residue,', 'NN', 'I-NP', 'I-protein')
('results', 'result', 'VBZ', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('much', 'much', 'RB', 'B-NP', 'O')
('closer', 'close', 'JJR', 'I-NP', 'O')
('contact', 'contact', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('adjacent', 'adjacent', 'JJ', 'I-NP', 'O')
('Val84', 'Val84', 'NN', 'I-NP', 'O')
('side', 'side', 'NN', 'I-NP', 'O')
('chain', 'chain', 'NN', 'I-NP', 'O')
('(2.98', '(2.98', 'CD', 'I-NP', 'O')
('Å', 'Å', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('mutant', 'mutant', 'JJ', 'B-NP', 'O')
('compared', 'compare', 'VBN', 'B-PP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('4.21', '4.21', 'CD', 'B-NP', 'O')
('Å', 'Å', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('wild-type)', 'wild-type)', 'NN', 'B-NP', 'B-protein')
('and', 'and', 'CC', 'O', 'O')
('forms', 'form', 'VBZ', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('new', 'new', 'JJ', 'I-NP', 'O')
('hydrogen', 'hydrogen', 'NN', 'I-NP', 'O')
('bond', 'bond', 'NN', 'I-NP', 'O')
('(2.39', '(2.39', 'CD', 'I-NP', 'O')
('Å)', 'Å)', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('carbonyl', 'carbonyl', 'NN', 'I-NP', 'O')
('group', 'group', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('Ser113', 'Ser113', 'NNP', 'B-NP', 'O')
('(Fig.', '(Fig.', 'NNP', 'I-NP', 'O')
2C, 2D).
('2C,', '2C,', 'NN', 'B-NP', 'O')
('2D).', '2D).', 'NN', 'I-NP', 'O')
The changes significantly decrease the electrostatic energy with a minimal change in CA1-CB1-CG1 bond angle (109.53o to 109.54o) but increase the energy of the whole protein considerably from 6,946.490 kJ/mol for wild-type to 7,316.498 kJ/mol for the mutated protein (Table 2).
('The', 'The', 'DT', 'B-NP', 'O')
('changes', 'change', 'NNS', 'I-NP', 'O')
('significantly', 'significantly', 'RB', 'B-ADVP', 'O')
('decrease', 'decrease', 'VBP', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('electrostatic', 'electrostatic', 'JJ', 'I-NP', 'O')
('energy', 'energy', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('minimal', 'minimal', 'JJ', 'I-NP', 'O')
('change', 'change', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('CA1-CB1-CG1', 'CA1-CB1-CG1', 'NN', 'B-NP', 'O')
('bond', 'bond', 'NN', 'I-NP', 'O')
('angle', 'angle', 'NN', 'I-NP', 'O')
('(109.53o', '(109.53o', 'CD', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('109.54o)', '109.54o)', 'CD', 'B-NP', 'O')
('but', 'but', 'CC', 'O', 'O')
('increase', 'increase', 'VB', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('energy', 'energy', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('whole', 'whole', 'JJ', 'I-NP', 'O')
('protein', 'protein', 'NN', 'I-NP', 'O')
('considerably', 'considerably', 'RB', 'B-ADVP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('6,946.490', '6,946.490', 'CD', 'B-NP', 'O')
('kJ/mol', 'kJ/mol', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('wild-type', 'wild-type', 'JJ', 'B-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('7,316.498', '7,316.498', 'CD', 'B-NP', 'O')
('kJ/mol', 'kJ/mol', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('mutated', 'mutate', 'VBN', 'I-NP', 'B-protein')
('protein', 'protein', 'NN', 'I-NP', 'I-protein')
('(Table', '(Table', 'JJ', 'I-NP', 'O')
('2).', '2).', 'CD', 'I-NP', 'O')
In addition, a connexin 26 mutation, Asn54 to Lys, shifts the interaction from 114 Glu to the CA and CG atoms of the protein's polar amino acid residue 110 Glu at a cutoff score of 2 with an additional increase in PI value from 5.41 for wild-type to 9.47 for the mutated residue and a charge reversal from a neutral to basic residue with a strong positive charge.
('In', 'In', 'IN', 'B-PP', 'O')
('addition,', 'addition,', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('connexin', 'connexin', 'NN', 'I-NP', 'O')
('26', '26', 'CD', 'I-NP', 'O')
('mutation,', 'mutation,', 'NN', 'I-NP', 'O')
('Asn54', 'Asn54', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('Lys,', 'Lys,', 'NN', 'B-NP', 'O')
('shifts', 'shift', 'NNS', 'I-NP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('interaction', 'interaction', 'NN', 'I-NP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('114', '114', 'CD', 'B-NP', 'O')
('Glu', 'Glu', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('CA', 'CA', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('CG', 'CG', 'NN', 'I-NP', 'O')
('atoms', 'atom', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
("protein's", "protein'", 'NNS', 'I-NP', 'O')
('polar', 'polar', 'JJ', 'B-NP', 'O')
('amino', 'amino', 'NN', 'I-NP', 'O')
('acid', 'acid', 'NN', 'I-NP', 'O')
('residue', 'residue', 'NN', 'I-NP', 'O')
('110', '110', 'CD', 'I-NP', 'O')
('Glu', 'Glu', 'NN', 'I-NP', 'O')
('at', 'at', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('cutoff', 'cutoff', 'NN', 'I-NP', 'O')
('score', 'score', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('2', '2', 'CD', 'B-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('additional', 'additional', 'JJ', 'I-NP', 'O')
('increase', 'increase', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('PI', 'PI', 'NN', 'B-NP', 'O')
('value', 'value', 'NN', 'I-NP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('5.41', '5.41', 'CD', 'B-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('wild-type', 'wild-type', 'JJ', 'B-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('9.47', '9.47', 'CD', 'B-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('mutated', 'mutate', 'VBN', 'I-NP', 'O')
('residue', 'residue', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('charge', 'charge', 'NN', 'I-NP', 'O')
('reversal', 'reversal', 'NN', 'I-NP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('neutral', 'neutral', 'JJ', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('basic', 'basic', 'JJ', 'B-NP', 'O')
('residue', 'residue', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('strong', 'strong', 'JJ', 'I-NP', 'O')
('positive', 'positive', 'JJ', 'I-NP', 'O')
('charge.', 'charge.', 'NN', 'I-NP', 'O')
The positively charged residue repels the positive ions and metabolites and thus impairs trafficking through ion channels of connexin proteins.
('The', 'The', 'DT', 'B-NP', 'O')
('positively', 'positively', 'RB', 'I-NP', 'O')
('charged', 'charge', 'VBN', 'I-NP', 'O')
('residue', 'residue', 'NN', 'I-NP', 'O')
('repels', 'repel', 'VBZ', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('positive', 'positive', 'JJ', 'I-NP', 'O')
('ions', 'ion', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('metabolites', 'metabolite', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('thus', 'thus', 'RB', 'B-VP', 'O')
('impairs', 'impair', 'VBZ', 'I-VP', 'O')
('trafficking', 'trafficking', 'NN', 'B-NP', 'O')
('through', 'through', 'IN', 'B-PP', 'O')
('ion', 'ion', 'NN', 'B-NP', 'O')
('channels', 'channel', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('connexin', 'connexin', 'NN', 'B-NP', 'O')
('proteins.', 'proteins.', 'NN', 'I-NP', 'O')
A decrease in signal for the next pathway causes syndromes and hearing impairment.
('A', 'A', 'DT', 'B-NP', 'O')
('decrease', 'decrease', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('signal', 'signal', 'NN', 'B-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('next', 'next', 'JJ', 'I-NP', 'O')
('pathway', 'pathway', 'NN', 'I-NP', 'O')
('causes', 'cause', 'VBZ', 'B-VP', 'O')
('syndromes', 'syndrome', 'NNS', 'B-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('hearing', 'hearing', 'NN', 'B-NP', 'O')
('impairment.', 'impairment.', 'NN', 'I-NP', 'O')
Mutations leading to Asp50Asn apparently do not affect peptide bonds or hydrogen bonding (Fig.
('Mutations', 'Mutation', 'NNS', 'B-NP', 'O')
('leading', 'lead', 'VBG', 'B-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('Asp50Asn', 'Asp50Asn', 'NN', 'B-NP', 'O')
('apparently', 'apparently', 'RB', 'B-ADVP', 'O')
('do', 'do', 'VBP', 'B-VP', 'O')
('not', 'not', 'RB', 'I-VP', 'O')
('affect', 'affect', 'VB', 'I-VP', 'O')
('peptide', 'peptide', 'NN', 'B-NP', 'O')
('bonds', 'bond', 'NNS', 'I-NP', 'O')
('or', 'or', 'CC', 'O', 'O')
('hydrogen', 'hydrogen', 'NN', 'B-NP', 'O')
('bonding', 'bonding', 'NN', 'I-NP', 'O')
('(Fig.', '(Fig.', 'NNP', 'B-NP', 'O')
2E, 2F) but significantly rotate the CA1CB1CG1 bond angle from 105.45o for wildtype to 111.17o for the mutated protein.
('2E,', '2E,', 'NN', 'B-NP', 'O')
('2F)', '2F)', 'NN', 'I-NP', 'O')
('but', 'but', 'CC', 'O', 'O')
('significantly', 'significantly', 'RB', 'B-VP', 'O')
('rotate', 'rotate', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('CA1CB1CG1', 'CA1CB1CG1', 'NN', 'I-NP', 'O')
('bond', 'bond', 'NN', 'I-NP', 'O')
('angle', 'angle', 'NN', 'I-NP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('105.45o', '105.45o', 'CD', 'B-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('wildtype', 'wildtype', 'NN', 'B-NP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('111.17o', '111.17o', 'VB', 'I-VP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('mutated', 'mutate', 'VBN', 'I-NP', 'O')
('protein.', 'protein.', 'NN', 'I-NP', 'O')
The CG1CB1 rotation cause a tremendous decrease in energy for bonds (63.585 kJ/mol for wildtype to 6.228 kJ/mol for mutant), and electrostatic energy decreases by 3.3 kJ/mol (11.46 kJ/mol for wildtype to 8.16k/mol for the mutant) with an overall decrease in the energy of the protein from 6946.490 kJ/mol to 6811.053 kJ/mol (Table 2).
('The', 'The', 'DT', 'B-NP', 'O')
('CG1CB1', 'CG1CB1', 'NN', 'I-NP', 'O')
('rotation', 'rotation', 'NN', 'I-NP', 'O')
('cause', 'cause', 'VBP', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('tremendous', 'tremendous', 'JJ', 'I-NP', 'O')
('decrease', 'decrease', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('energy', 'energy', 'NN', 'B-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('bonds', 'bond', 'NNS', 'B-NP', 'O')
('(63.585', '(63.585', 'CD', 'B-NP', 'O')
('kJ/mol', 'kJ/mol', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('wildtype', 'wildtype', 'NN', 'B-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('6.228', '6.228', 'CD', 'B-NP', 'O')
('kJ/mol', 'kJ/mol', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('mutant),', 'mutant),', 'NN', 'B-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('electrostatic', 'electrostatic', 'JJ', 'B-NP', 'O')
('energy', 'energy', 'NN', 'I-NP', 'O')
('decreases', 'decrease', 'VBZ', 'B-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('3.3', '3.3', 'CD', 'B-NP', 'O')
('kJ/mol', 'kJ/mol', 'NN', 'I-NP', 'O')
('(11.46', '(11.46', 'NN', 'I-NP', 'O')
('kJ/mol', 'kJ/mol', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('wildtype', 'wildtype', 'NN', 'B-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('8.16k/mol', '8.16k/mol', 'NN', 'B-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('mutant)', 'mutant)', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('overall', 'overall', 'JJ', 'I-NP', 'O')
('decrease', 'decrease', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('energy', 'energy', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('protein', 'protein', 'NN', 'I-NP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('6946.490', '6946.490', 'CD', 'B-NP', 'O')
('kJ/mol', 'kJ/mol', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('6811.053', '6811.053', 'CD', 'B-NP', 'O')
('kJ/mol', 'kJ/mol', 'NN', 'I-NP', 'O')
('(Table', '(Table', 'JJ', 'B-ADJP', 'O')
('2).', '2).', 'CD', 'B-NP', 'O')
In addition, the connexin 26 mutation Asp50Asn results in a considerable increase in PI value from 2.77 in the wildtype to 5.41 for the mutated residue.
('In', 'In', 'IN', 'B-PP', 'O')
('addition,', 'addition,', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('connexin', 'connexin', 'NN', 'I-NP', 'O')
('26', '26', 'CD', 'I-NP', 'O')
('mutation', 'mutation', 'NN', 'I-NP', 'O')
('Asp50Asn', 'Asp50Asn', 'NN', 'I-NP', 'O')
('results', 'result', 'VBZ', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('considerable', 'considerable', 'JJ', 'I-NP', 'O')
('increase', 'increase', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('PI', 'PI', 'NN', 'B-NP', 'O')
('value', 'value', 'NN', 'I-NP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('2.77', '2.77', 'CD', 'B-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('wildtype', 'wildtype', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('5.41', '5.41', 'CD', 'B-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('mutated', 'mutate', 'VBN', 'I-NP', 'O')
('residue.', 'residue.', 'NN', 'I-NP', 'O')
This inhibits the Van der Waals interaction of the OD1 and OD2 atoms of the Asp50 side chains to the backbone oxygen atom of Glu47 at a cutoff score of 2.
('This', 'This', 'DT', 'B-NP', 'O')
('inhibits', 'inhibit', 'VBZ', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('Van', 'Van', 'NNP', 'I-NP', 'O')
('der', 'der', 'NN', 'I-NP', 'O')
('Waals', 'Waal', 'VBZ', 'B-VP', 'O')
('interaction', 'interaction', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('OD1', 'OD1', 'NN', 'I-NP', 'B-protein')
('and', 'and', 'CC', 'I-NP', 'O')
('OD2', 'OD2', 'NN', 'I-NP', 'O')
('atoms', 'atom', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('Asp50', 'Asp50', 'NN', 'I-NP', 'B-protein')
('side', 'side', 'NN', 'I-NP', 'I-protein')
('chains', 'chain', 'NNS', 'I-NP', 'I-protein')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('backbone', 'backbone', 'NN', 'I-NP', 'O')
('oxygen', 'oxygen', 'NN', 'I-NP', 'O')
('atom', 'atom', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('Glu47', 'Glu47', 'NN', 'B-NP', 'B-protein')
('at', 'at', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('cutoff', 'cutoff', 'NN', 'I-NP', 'O')
('score', 'score', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('2.', '2.', 'CD', 'B-NP', 'O')
Alterations in atomic interaction and a charge reversal from negative to neutral result in impaired trafficking of positive ions and metabolites, such as calcium and potassium ions, with reduced transportation and signaling to the next pathways and, ultimately, cell death.
('Alterations', 'Alteration', 'NNS', 'B-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('atomic', 'atomic', 'JJ', 'B-NP', 'O')
('interaction', 'interaction', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('charge', 'charge', 'NN', 'I-NP', 'O')
('reversal', 'reversal', 'NN', 'I-NP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('negative', 'negative', 'JJ', 'B-ADJP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('neutral', 'neutral', 'JJ', 'B-NP', 'O')
('result', 'result', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('impaired', 'impaired', 'JJ', 'B-NP', 'O')
('trafficking', 'trafficking', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('positive', 'positive', 'JJ', 'B-NP', 'O')
('ions', 'ion', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('metabolites,', 'metabolites,', 'NN', 'B-NP', 'O')
('such', 'such', 'JJ', 'B-PP', 'O')
('as', 'as', 'IN', 'I-PP', 'O')
('calcium', 'calcium', 'NN', 'B-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('potassium', 'potassium', 'NN', 'I-NP', 'O')
('ions,', 'ions,', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('reduced', 'reduce', 'VBN', 'B-NP', 'O')
('transportation', 'transportation', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('signaling', 'signaling', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('next', 'next', 'JJ', 'I-NP', 'O')
('pathways', 'pathway', 'NNS', 'I-NP', 'O')
('and,', 'and,', 'CC', 'O', 'O')
('ultimately,', 'ultimately,', 'NN', 'B-NP', 'O')
('cell', 'cell', 'NN', 'I-NP', 'O')
('death.', 'death.', 'NN', 'I-NP', 'O')
The long arm of human chromosome 13 holds a very important gene, GJB2, related to proper hearing (Castillo et al., 2005).
('The', 'The', 'DT', 'B-NP', 'O')
('long', 'long', 'JJ', 'I-NP', 'O')
('arm', 'arm', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('human', 'human', 'JJ', 'B-NP', 'B-DNA')
('chromosome', 'chromosome', 'NN', 'I-NP', 'I-DNA')
('13', '13', 'CD', 'I-NP', 'I-DNA')
('holds', 'hold', 'VBZ', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('very', 'very', 'RB', 'I-NP', 'O')
('important', 'important', 'JJ', 'I-NP', 'O')
('gene,', 'gene,', 'NN', 'I-NP', 'O')
('GJB2,', 'GJB2,', 'NN', 'I-NP', 'O')
('related', 'relate', 'VBN', 'B-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('proper', 'proper', 'JJ', 'B-NP', 'O')
('hearing', 'hearing', 'NN', 'I-NP', 'O')
('(Castillo', '(Castillo', 'NNP', 'I-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2005).', '2005).', 'CD', 'B-NP', 'O')
The gene GJB2 translates into the connexin protein, which belongs to the connexin family in vertebrates.
('The', 'The', 'DT', 'B-NP', 'O')
('gene', 'gene', 'NN', 'I-NP', 'O')
('GJB2', 'GJB2', 'NN', 'I-NP', 'B-protein')
('translates', 'translate', 'VBZ', 'B-VP', 'O')
('into', 'into', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('connexin', 'connexin', 'NN', 'I-NP', 'O')
('protein,', 'protein,', 'NN', 'I-NP', 'O')
('which', 'which', 'WDT', 'B-NP', 'O')
('belongs', 'belong', 'VBZ', 'B-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('connexin', 'connexin', 'NN', 'I-NP', 'B-protein')
('family', 'family', 'NN', 'I-NP', 'I-protein')
('in', 'in', 'IN', 'B-PP', 'O')
('vertebrates.', 'vertebrates.', 'NN', 'B-NP', 'O')
One of the proteins, connexin 26, transcribed by the gap junction β-2 gene, belongs to a group of structurally similar trans-proteins that assemble each other and form gap junctions (Soninsky, 1995).
('One', 'One', 'CD', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('proteins,', 'proteins,', 'NN', 'I-NP', 'O')
('connexin', 'connexin', 'NN', 'I-NP', 'O')
('26,', '26,', 'CD', 'I-NP', 'O')
('transcribed', 'transcribe', 'VBN', 'B-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('gap', 'gap', 'NN', 'I-NP', 'B-protein')
('junction', 'junction', 'NN', 'I-NP', 'I-protein')
('β-2', 'β-2', 'NN', 'I-NP', 'I-protein')
('gene,', 'gene,', 'NN', 'I-NP', 'I-protein')
('belongs', 'belong', 'VBZ', 'B-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('group', 'group', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('structurally', 'structurally', 'RB', 'B-NP', 'B-protein')
('similar', 'similar', 'JJ', 'I-NP', 'I-protein')
('trans-proteins', 'trans-protein', 'NNS', 'I-NP', 'I-protein')
('that', 'that', 'WDT', 'B-NP', 'O')
('assemble', 'assemble', 'VBP', 'B-VP', 'O')
('each', 'each', 'DT', 'B-NP', 'O')
('other', 'other', 'JJ', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('form', 'form', 'NN', 'I-NP', 'O')
('gap', 'gap', 'NN', 'I-NP', 'O')
('junctions', 'junction', 'NNS', 'I-NP', 'O')
('(Soninsky,', '(Soninsky,', 'NNP', 'B-NP', 'O')
('1995).', '1995).', 'CD', 'I-NP', 'O')
This protein is colocalized to connexin 30 and permits the transfer of ions and small molecules in their adjacent cells.
('This', 'This', 'DT', 'B-NP', 'O')
('protein', 'protein', 'NN', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('colocalized', 'colocalize', 'VBN', 'I-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('connexin', 'connexin', 'NN', 'B-NP', 'O')
('30', '30', 'CD', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('permits', 'permit', 'VBZ', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('transfer', 'transfer', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('ions', 'ion', 'NNS', 'B-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('small', 'small', 'JJ', 'B-NP', 'O')
('molecules', 'molecule', 'NNS', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('their', 'their', 'PRP$', 'B-NP', 'O')
('adjacent', 'adjacent', 'JJ', 'I-NP', 'O')
('cells.', 'cells.', 'NNS', 'I-NP', 'O')
In such a way, the protein couples the various cells both metabolically and electrically and maintains the cellular homeostasis (Mahasneh and Battah, 2006).
('In', 'In', 'IN', 'B-PP', 'O')
('such', 'such', 'PDT', 'B-NP', 'O')
('a', 'a', 'DT', 'I-NP', 'O')
('way,', 'way,', 'NN', 'I-NP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('protein', 'protein', 'NN', 'I-NP', 'O')
('couples', 'couple', 'VBZ', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('various', 'various', 'JJ', 'I-NP', 'O')
('cells', 'cell', 'NNS', 'I-NP', 'O')
('both', 'both', 'CC', 'O', 'O')
('metabolically', 'metabolically', 'RB', 'B-ADVP', 'O')
('and', 'and', 'CC', 'I-ADVP', 'O')
('electrically', 'electrically', 'RB', 'I-ADVP', 'O')
('and', 'and', 'CC', 'O', 'O')
('maintains', 'maintain', 'VBZ', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('cellular', 'cellular', 'JJ', 'I-NP', 'O')
('homeostasis', 'homeostasis', 'NN', 'I-NP', 'O')
('(Mahasneh', '(Mahasneh', 'NNP', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('Battah,', 'Battah,', 'NNP', 'B-NP', 'O')
('2006).', '2006).', 'CD', 'I-NP', 'O')
Connexin 26 mutations are the cause of nonsyndromic recessive and dominant forms of hearing impairment (Kelsell et al., 1997).
('Connexin', 'Connexin', 'NN', 'B-NP', 'O')
('26', '26', 'CD', 'B-NP', 'O')
('mutations', 'mutation', 'NNS', 'I-NP', 'O')
('are', 'be', 'VBP', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('cause', 'cause', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('nonsyndromic', 'nonsyndromic', 'JJ', 'B-NP', 'O')
('recessive', 'recessive', 'JJ', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('dominant', 'dominant', 'JJ', 'I-NP', 'O')
('forms', 'form', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('hearing', 'hear', 'VBG', 'B-VP', 'O')
('impairment', 'impairment', 'NN', 'B-NP', 'O')
('(Kelsell', '(Kelsell', 'NNP', 'I-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('1997).', '1997).', 'CD', 'B-NP', 'O')
A point mutation at nucleotide 162 in codon 54 changes C to A.
('A', 'A', 'DT', 'B-NP', 'O')
('point', 'point', 'NN', 'I-NP', 'O')
('mutation', 'mutation', 'NN', 'I-NP', 'O')
('at', 'at', 'IN', 'B-PP', 'O')
('nucleotide', 'nucleotide', 'NN', 'B-NP', 'O')
('162', '162', 'CD', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('codon', 'codon', 'NN', 'B-NP', 'B-cell_line')
('54', '54', 'CD', 'I-NP', 'I-cell_line')
('changes', 'change', 'NNS', 'I-NP', 'I-cell_line')
('C', 'C', 'NN', 'I-NP', 'I-cell_line')
('to', 'to', 'TO', 'B-PP', 'O')
('A.', 'A.', 'NN', 'B-NP', 'O')
This substitution leads to the replacement of the evolutionarily conserved asparagine 54 to an electronegatively charged lysine in the first expended loop of connexin 26 (Richard et al., 2004).
('This', 'This', 'DT', 'B-NP', 'O')
('substitution', 'substitution', 'NN', 'I-NP', 'O')
('leads', 'lead', 'VBZ', 'B-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('replacement', 'replacement', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('evolutionarily', 'evolutionarily', 'RB', 'I-NP', 'O')
('conserved', 'conserve', 'VBN', 'I-NP', 'O')
('asparagine', 'asparagine', 'NN', 'I-NP', 'O')
('54', '54', 'CD', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('electronegatively', 'electronegatively', 'RB', 'I-NP', 'O')
('charged', 'charge', 'VBN', 'I-NP', 'O')
('lysine', 'lysine', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('first', 'first', 'JJ', 'I-NP', 'O')
('expended', 'expend', 'VBN', 'I-NP', 'O')
('loop', 'loop', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('connexin', 'connexin', 'NN', 'B-NP', 'O')
('26', '26', 'CD', 'I-NP', 'O')
('(Richard', '(Richard', 'NNP', 'I-NP', 'O')
('et', 'et', 'NN', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2004).', '2004).', 'CD', 'B-NP', 'O')
The resultant mutation destroys the hydrogen bond from the amide group of Leu56 (Fig.
('The', 'The', 'DT', 'B-NP', 'O')
('resultant', 'resultant', 'JJ', 'I-NP', 'O')
('mutation', 'mutation', 'NN', 'I-NP', 'O')
('destroys', 'destroy', 'VBZ', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('hydrogen', 'hydrogen', 'NN', 'I-NP', 'O')
('bond', 'bond', 'NN', 'I-NP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('amide', 'amide', 'NN', 'I-NP', 'O')
('group', 'group', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('Leu56', 'Leu56', 'NNP', 'B-NP', 'O')
('(Fig.', '(Fig.', 'NNP', 'I-NP', 'O')
2D).
('2D).', '2D).', 'LS', 'B-LST', 'O')
Additional methyl groups of Leu54 extend to Ser113, and the carbonyl group of Ser113 shares a hydrogen bond with the Lys54 amide group (Fig.
('Additional', 'Additional', 'JJ', 'B-NP', 'O')
('methyl', 'methyl', 'NN', 'I-NP', 'O')
('groups', 'group', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('Leu54', 'Leu54', 'NN', 'B-NP', 'B-protein')
('extend', 'extend', 'VBP', 'B-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('Ser113,', 'Ser113,', 'NN', 'B-NP', 'B-protein')
('and', 'and', 'CC', 'O', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('carbonyl', 'carbonyl', 'NN', 'I-NP', 'O')
('group', 'group', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('Ser113', 'Ser113', 'NN', 'B-NP', 'O')
('shares', 'share', 'VBZ', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('hydrogen', 'hydrogen', 'NN', 'I-NP', 'O')
('bond', 'bond', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('Lys54', 'Lys54', 'NN', 'I-NP', 'O')
('amide', 'amide', 'NN', 'I-NP', 'O')
('group', 'group', 'NN', 'I-NP', 'O')
('(Fig.', '(Fig.', 'NN', 'I-NP', 'O')
2D).
('2D).', '2D).', 'LS', 'B-LST', 'O')
Such subtle changes alter the energy of the whole protein from 6946.490 kJ/mol to 7316.498 kJ/mol (Table 2).
('Such', 'Such', 'JJ', 'B-NP', 'O')
('subtle', 'subtle', 'NN', 'I-NP', 'O')
('changes', 'change', 'NNS', 'I-NP', 'O')
('alter', 'alter', 'VBP', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('energy', 'energy', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('whole', 'whole', 'JJ', 'I-NP', 'O')
('protein', 'protein', 'NN', 'I-NP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('6946.490', '6946.490', 'CD', 'B-NP', 'O')
('kJ/mol', 'kJ/mol', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('7316.498', '7316.498', 'CD', 'B-NP', 'O')
('kJ/mol', 'kJ/mol', 'NN', 'I-NP', 'O')
('(Table', '(Table', 'JJ', 'B-ADJP', 'O')
('2).', '2).', 'CD', 'B-NP', 'O')
These changes might be involved in reducing the expression of connexin 26, causing Kunckle pads and leukonychia (Bart et al., 1967).
('These', 'These', 'DT', 'B-NP', 'O')
('changes', 'change', 'NNS', 'I-NP', 'O')
('might', 'might', 'MD', 'B-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('involved', 'involve', 'VBN', 'I-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('reducing', 'reduce', 'VBG', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('expression', 'expression', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('connexin', 'connexin', 'NN', 'B-NP', 'O')
('26,', '26,', 'CD', 'I-NP', 'O')
('causing', 'cause', 'VBG', 'B-VP', 'O')
('Kunckle', 'Kunckle', 'NNP', 'B-NP', 'O')
('pads', 'pad', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('leukonychia', 'leukonychia', 'NN', 'B-NP', 'O')
('(Bart', '(Bart', 'NNP', 'I-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('1967).', '1967).', 'CD', 'B-NP', 'O')
Affected family members suffer from thickened skin of the palms and soles in early childhood (Richard et al., 2004).
('Affected', 'Affect', 'VBN', 'B-NP', 'O')
('family', 'family', 'NN', 'I-NP', 'O')
('members', 'member', 'NNS', 'I-NP', 'O')
('suffer', 'suffer', 'VBP', 'B-VP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('thickened', 'thicken', 'VBN', 'B-NP', 'O')
('skin', 'skin', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('palms', 'palm', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('soles', 'sol', 'NNS', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('early', 'early', 'JJ', 'B-NP', 'O')
('childhood', 'childhood', 'NN', 'I-NP', 'O')
('(Richard', '(Richard', 'NNP', 'I-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2004).', '2004).', 'CD', 'B-NP', 'O')
The mutation Asn54Lys disturbs the hydrogen bonds and seems to be a contributing factor toward reduced epidermal expression of connexin 26, also involved in BartPumphrey Syndrome (Richard et al., 2004).
('The', 'The', 'DT', 'B-NP', 'O')
('mutation', 'mutation', 'NN', 'I-NP', 'O')
('Asn54Lys', 'Asn54Lys', 'NN', 'I-NP', 'O')
('disturbs', 'disturb', 'VBZ', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('hydrogen', 'hydrogen', 'NN', 'I-NP', 'O')
('bonds', 'bond', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('seems', 'seem', 'VBZ', 'B-VP', 'O')
('to', 'to', 'TO', 'I-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('contributing', 'contribute', 'VBG', 'I-NP', 'O')
('factor', 'factor', 'NN', 'I-NP', 'O')
('toward', 'toward', 'IN', 'B-PP', 'O')
('reduced', 'reduce', 'VBN', 'B-NP', 'O')
('epidermal', 'epidermal', 'JJ', 'I-NP', 'O')
('expression', 'expression', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('connexin', 'connexin', 'NN', 'B-NP', 'O')
('26,', '26,', 'CD', 'I-NP', 'O')
('also', 'also', 'RB', 'B-ADVP', 'O')
('involved', 'involve', 'VBN', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('BartPumphrey', 'BartPumphrey', 'NNP', 'B-NP', 'O')
('Syndrome', 'Syndrome', 'NNP', 'I-NP', 'O')
('(Richard', '(Richard', 'NNP', 'I-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2004).', '2004).', 'CD', 'B-NP', 'O')
The dominant point mutation of gap junction β2, causing Asp50Asn, significantly reduces the energy for bonds (63.585 kJ/mol for wild-type to 6.228 kJ/mol for mutant).
('The', 'The', 'DT', 'B-NP', 'O')
('dominant', 'dominant', 'JJ', 'I-NP', 'O')
('point', 'point', 'NN', 'I-NP', 'O')
('mutation', 'mutation', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('gap', 'gap', 'NN', 'B-NP', 'B-protein')
('junction', 'junction', 'NN', 'I-NP', 'I-protein')
('β2,', 'β2,', 'NN', 'I-NP', 'I-protein')
('causing', 'cause', 'VBG', 'B-VP', 'I-protein')
('Asp50Asn,', 'Asp50Asn,', 'NN', 'B-NP', 'I-protein')
('significantly', 'significantly', 'RB', 'B-VP', 'O')
('reduces', 'reduce', 'VBZ', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('energy', 'energy', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('bonds', 'bond', 'NNS', 'B-NP', 'O')
('(63.585', '(63.585', 'CD', 'B-NP', 'O')
('kJ/mol', 'kJ/mol', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('wild-type', 'wild-type', 'JJ', 'B-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('6.228', '6.228', 'CD', 'B-NP', 'O')
('kJ/mol', 'kJ/mol', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('mutant).', 'mutant).', 'NN', 'B-NP', 'O')
The CB1-CG1 bond rotation affects the angle (105.45o for wild-type to 111.17o for mutant) and the decrease in the force field energy of the protein from 6946.490 kJ/mol to 6811.053 kJ/mol (Table 2).
('The', 'The', 'DT', 'B-NP', 'O')
('CB1-CG1', 'CB1-CG1', 'NN', 'I-NP', 'O')
('bond', 'bond', 'NN', 'I-NP', 'O')
('rotation', 'rotation', 'NN', 'I-NP', 'O')
('affects', 'affect', 'VBZ', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('angle', 'angle', 'JJ', 'I-NP', 'O')
('(105.45o', '(105.45o', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('wild-type', 'wild-type', 'JJ', 'B-ADJP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('111.17o', '111.17o', 'VB', 'I-VP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('mutant)', 'mutant)', 'NN', 'B-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('decrease', 'decrease', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('force', 'force', 'NN', 'I-NP', 'O')
('field', 'field', 'NN', 'I-NP', 'O')
('energy', 'energy', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('protein', 'protein', 'NN', 'I-NP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('6946.490', '6946.490', 'CD', 'B-NP', 'O')
('kJ/mol', 'kJ/mol', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('6811.053', '6811.053', 'CD', 'B-NP', 'O')
('kJ/mol', 'kJ/mol', 'NN', 'I-NP', 'O')
('(Table', '(Table', 'JJ', 'B-ADJP', 'O')
('2).', '2).', 'CD', 'B-NP', 'O')
The substitution of the conserved residue aspartic acid 50 by asparagine (Asp50Asn) in the first extracellular domain of connexin 26 causes Keratitis-IchthyosisDeafness Syndrome (Yotsumoto et al., 2003).
('The', 'The', 'DT', 'B-NP', 'O')
('substitution', 'substitution', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('conserved', 'conserve', 'VBN', 'I-NP', 'O')
('residue', 'residue', 'NN', 'I-NP', 'O')
('aspartic', 'aspartic', 'JJ', 'I-NP', 'O')
('acid', 'acid', 'NN', 'I-NP', 'O')
('50', '50', 'CD', 'I-NP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('asparagine', 'asparagine', 'NN', 'B-NP', 'O')
('(Asp50Asn)', '(Asp50Asn)', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('first', 'first', 'JJ', 'I-NP', 'B-protein')
('extracellular', 'extracellular', 'JJ', 'I-NP', 'I-protein')
('domain', 'domain', 'NN', 'I-NP', 'I-protein')
('of', 'of', 'IN', 'B-PP', 'O')
('connexin', 'connexin', 'NN', 'B-NP', 'O')
('26', '26', 'CD', 'I-NP', 'O')
('causes', 'cause', 'VBZ', 'B-VP', 'O')
('Keratitis-IchthyosisDeafness', 'Keratitis-IchthyosisDeafness', 'NNP', 'B-NP', 'O')
('Syndrome', 'Syndrome', 'NNP', 'I-NP', 'O')
('(Yotsumoto', '(Yotsumoto', 'NNP', 'I-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2003).', '2003).', 'CD', 'B-NP', 'O')
This mutation is likely to be the factor that disturbs the communication of ions, metabolites, and signaling molecules in neighboring cells and affects homeostasis by disturbing the bonding and energies (Saez et al., 2000).
('This', 'This', 'DT', 'B-NP', 'O')
('mutation', 'mutation', 'NN', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('likely', 'likely', 'JJ', 'B-ADJP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('factor', 'factor', 'NN', 'I-NP', 'O')
('that', 'that', 'WDT', 'B-NP', 'O')
('disturbs', 'disturb', 'VBZ', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('communication', 'communication', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('ions,', 'ions,', 'NN', 'B-NP', 'O')
('metabolites,', 'metabolites,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('signaling', 'signal', 'VBG', 'B-VP', 'B-protein')
('molecules', 'molecule', 'NNS', 'B-NP', 'I-protein')
('in', 'in', 'IN', 'B-PP', 'O')
('neighboring', 'neighbor', 'VBG', 'B-NP', 'O')
('cells', 'cell', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('affects', 'affect', 'VBZ', 'B-VP', 'O')
('homeostasis', 'homeostasis', 'NN', 'B-NP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('disturbing', 'disturb', 'VBG', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('bonding', 'bonding', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('energies', 'energy', 'VBZ', 'B-VP', 'O')
('(Saez', '(Saez', 'NNP', 'B-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2000).', '2000).', 'CD', 'B-NP', 'O')
Charge reversal and the reduced distance of His66 to Pro70 due to Asp66His alter the normal protein bonding (Fig.
('Charge', 'Charge', 'NN', 'B-NP', 'O')
('reversal', 'reversal', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('reduced', 'reduce', 'VBN', 'I-NP', 'O')
('distance', 'distance', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('His66', 'His66', 'NN', 'B-NP', 'B-protein')
('to', 'to', 'TO', 'B-PP', 'O')
('Pro70', 'Pro70', 'NN', 'B-NP', 'B-protein')
('due', 'due', 'JJ', 'B-ADJP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('Asp66His', 'Asp66His', 'NN', 'B-NP', 'O')
('alter', 'alter', 'VB', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('normal', 'normal', 'JJ', 'I-NP', 'O')
('protein', 'protein', 'NN', 'I-NP', 'O')
('bonding', 'bond', 'VBG', 'B-VP', 'O')
('(Fig.', '(Fig.', 'NNP', 'B-NP', 'O')
2B), causing Vohwinkel syndrome (Snoeckx et al., 2005).
('2B),', '2B),', 'NN', 'B-NP', 'O')
('causing', 'cause', 'VBG', 'B-VP', 'O')
('Vohwinkel', 'Vohwinkel', 'NNP', 'B-NP', 'O')
('syndrome', 'syndrome', 'NN', 'I-NP', 'O')
('(Snoeckx', '(Snoeckx', 'NNP', 'I-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2005).', '2005).', 'CD', 'B-NP', 'O')
This might result in impaired trafficking of connexin 26, its assembly with other proteins, and docking with adjacent cells (Maestrini, et al., 1999; Marziano, et al., 2003).
('This', 'This', 'DT', 'B-NP', 'O')
('might', 'might', 'MD', 'B-VP', 'O')
('result', 'result', 'VB', 'I-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('impaired', 'impaired', 'JJ', 'B-NP', 'O')
('trafficking', 'trafficking', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('connexin', 'connexin', 'NN', 'B-NP', 'O')
('26,', '26,', 'CD', 'I-NP', 'O')
('its', 'its', 'PRP$', 'B-NP', 'O')
('assembly', 'assembly', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('other', 'other', 'JJ', 'B-NP', 'O')
('proteins,', 'proteins,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('docking', 'docking', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('adjacent', 'adjacent', 'JJ', 'B-NP', 'B-cell_type')
('cells', 'cell', 'NNS', 'I-NP', 'I-cell_type')
('(Maestrini,', '(Maestrini,', 'NNP', 'B-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al.,', 'al.,', ',', 'O', 'O')
('1999;', '1999;', 'CD', 'B-NP', 'O')
('Marziano,', 'Marziano,', 'NNP', 'I-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2003).', '2003).', 'CD', 'B-NP', 'O')
Normally, connexin assembles at the planer of the plasma membrane involved in the formation of the gap junction plaque.
('Normally,', 'Normally,', 'NN', 'B-NP', 'O')
('connexin', 'connexin', 'NN', 'I-NP', 'O')
('assembles', 'assemble', 'VBZ', 'B-VP', 'O')
('at', 'at', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('planer', 'planer', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('plasma', 'plasma', 'NN', 'I-NP', 'O')
('membrane', 'membrane', 'NN', 'I-NP', 'O')
('involved', 'involve', 'VBN', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('formation', 'formation', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('gap', 'gap', 'NN', 'I-NP', 'O')
('junction', 'junction', 'NN', 'I-NP', 'O')
('plaque.', 'plaque.', 'NN', 'I-NP', 'O')
Asp66His enlarges the CA1CB1 CG1 angle from 108.76o to 115.05o.
('Asp66His', 'Asp66His', 'NN', 'B-NP', 'O')
('enlarges', 'enlarge', 'VBZ', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('CA1CB1', 'CA1CB1', 'NN', 'I-NP', 'O')
('CG1', 'CG1', 'NN', 'I-NP', 'O')
('angle', 'angle', 'NN', 'I-NP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('108.76o', '108.76o', 'CD', 'B-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('115.05o.', '115.05o.', 'CD', 'B-NP', 'O')
Such factors might be involved in contributing to the plane of connexin 26, disturbing the members of the whole connexin unit, which ultimately affects membranous communication and results in hearing loss and skin diseases.
('Such', 'Such', 'JJ', 'B-NP', 'B-protein')
('factors', 'factor', 'NNS', 'I-NP', 'I-protein')
('might', 'might', 'MD', 'B-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('involved', 'involve', 'VBN', 'I-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('contributing', 'contribute', 'VBG', 'B-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('plane', 'plane', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('connexin', 'connexin', 'NN', 'B-NP', 'O')
('26,', '26,', 'CD', 'I-NP', 'O')
('disturbing', 'disturb', 'VBG', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('members', 'member', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('whole', 'whole', 'JJ', 'I-NP', 'O')
('connexin', 'connexin', 'NN', 'I-NP', 'O')
('unit,', 'unit,', 'NN', 'I-NP', 'O')
('which', 'which', 'WDT', 'B-NP', 'O')
('ultimately', 'ultimately', 'RB', 'B-ADVP', 'O')
('affects', 'affect', 'VBZ', 'B-VP', 'O')
('membranous', 'membranous', 'JJ', 'B-NP', 'O')
('communication', 'communication', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('results', 'result', 'VBZ', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('hearing', 'hear', 'VBG', 'B-VP', 'O')
('loss', 'loss', 'NN', 'B-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('skin', 'skin', 'NN', 'I-NP', 'O')
('diseases.', 'diseases.', 'NNS', 'I-NP', 'O')
Connexin 26 is an important protein involved in normal hearing.
('Connexin', 'Connexin', 'NN', 'B-NP', 'O')
('26', '26', 'CD', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('important', 'important', 'JJ', 'I-NP', 'O')
('protein', 'protein', 'NN', 'I-NP', 'O')
('involved', 'involve', 'VBN', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('normal', 'normal', 'JJ', 'B-NP', 'O')
('hearing.', 'hearing.', 'NN', 'I-NP', 'O')
Mutations affect the protein's function by disturbing the associated factors.
('Mutations', 'Mutation', 'NNS', 'B-NP', 'O')
('affect', 'affect', 'VBP', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
("protein's", "protein'", 'NNS', 'I-NP', 'O')
('function', 'function', 'NN', 'I-NP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('disturbing', 'disturb', 'VBG', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('associated', 'associate', 'VBN', 'I-NP', 'O')
('factors.', 'factors.', 'NN', 'I-NP', 'O')
However, similar to various other proteins, normal functioning of connexin 26 is associated with a range of factors.
('However,', 'However,', 'WRB', 'B-ADJP', 'O')
('similar', 'similar', 'JJ', 'I-ADJP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('various', 'various', 'JJ', 'B-NP', 'O')
('other', 'other', 'JJ', 'I-NP', 'O')
('proteins,', 'proteins,', 'NN', 'I-NP', 'O')
('normal', 'normal', 'JJ', 'I-NP', 'O')
('functioning', 'functioning', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('connexin', 'connexin', 'NN', 'B-NP', 'O')
('26', '26', 'CD', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('associated', 'associate', 'VBN', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('range', 'range', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('factors.', 'factors.', 'NN', 'B-NP', 'O')
Hydrogen bonding, residual energies, atomic angles, and residual charges are the main contributing factors that affect ion channels and their transportation.
('Hydrogen', 'Hydrogen', 'NN', 'B-NP', 'O')
('bonding,', 'bonding,', 'NN', 'I-NP', 'O')
('residual', 'residual', 'JJ', 'I-NP', 'O')
('energies,', 'energies,', 'NN', 'I-NP', 'O')
('atomic', 'atomic', 'JJ', 'I-NP', 'O')
('angles,', 'angles,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('residual', 'residual', 'JJ', 'B-NP', 'O')
('charges', 'charge', 'NNS', 'I-NP', 'O')
('are', 'be', 'VBP', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('main', 'main', 'JJ', 'I-NP', 'B-protein')
('contributing', 'contribute', 'VBG', 'I-NP', 'I-protein')
('factors', 'factor', 'NNS', 'I-NP', 'I-protein')
('that', 'that', 'WDT', 'B-NP', 'O')
('affect', 'affect', 'VBP', 'B-VP', 'O')
('ion', 'ion', 'NN', 'B-NP', 'O')
('channels', 'channel', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('their', 'their', 'PRP$', 'B-NP', 'O')
('transportation.', 'transportation.', 'NN', 'I-NP', 'O')
This significant increase in PI value is an additional cause of charge reversal of amino acid residues, which repels ions and metabolites and their passage through ion channels, inhibiting the next signaling pathway and causing syndromes.
('This', 'This', 'DT', 'B-NP', 'O')
('significant', 'significant', 'JJ', 'I-NP', 'O')
('increase', 'increase', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('PI', 'PI', 'NN', 'B-NP', 'O')
('value', 'value', 'NN', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('additional', 'additional', 'JJ', 'I-NP', 'O')
('cause', 'cause', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('charge', 'charge', 'NN', 'B-NP', 'O')
('reversal', 'reversal', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('amino', 'amino', 'JJ', 'B-NP', 'B-protein')
('acid', 'acid', 'NN', 'I-NP', 'I-protein')
('residues,', 'residues,', 'NN', 'I-NP', 'I-protein')
('which', 'which', 'WDT', 'B-NP', 'O')
('repels', 'repel', 'VBZ', 'B-VP', 'O')
('ions', 'ion', 'NNS', 'B-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('metabolites', 'metabolite', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('their', 'their', 'PRP$', 'B-NP', 'O')
('passage', 'passage', 'NN', 'I-NP', 'O')
('through', 'through', 'IN', 'B-PP', 'O')
('ion', 'ion', 'NN', 'B-NP', 'O')
('channels,', 'channels,', 'NN', 'I-NP', 'O')
('inhibiting', 'inhibit', 'VBG', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('next', 'next', 'JJ', 'I-NP', 'O')
('signaling', 'signaling', 'NN', 'I-NP', 'O')
('pathway', 'pathway', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('causing', 'cause', 'VBG', 'B-VP', 'O')
('syndromes.', 'syndromes.', 'NN', 'B-NP', 'O')
So, this study could be used as a reference for establishing a mechanism that could inhibit the repletion of ions and metabolites but push them back on their normal track.
('So,', 'So,', 'RB', 'B-ADVP', 'O')
('this', 'this', 'DT', 'B-NP', 'O')
('study', 'study', 'NN', 'I-NP', 'O')
('could', 'could', 'MD', 'B-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('used', 'use', 'VBN', 'I-VP', 'O')
('as', 'as', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('reference', 'reference', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('establishing', 'establish', 'VBG', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('mechanism', 'mechanism', 'NN', 'I-NP', 'O')
('that', 'that', 'WDT', 'B-NP', 'O')
('could', 'could', 'MD', 'B-VP', 'O')
('inhibit', 'inhibit', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('repletion', 'repletion', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('ions', 'ion', 'NNS', 'B-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('metabolites', 'metabolite', 'NNS', 'I-NP', 'O')
('but', 'but', 'CC', 'O', 'O')
('push', 'push', 'VB', 'B-VP', 'O')
('them', 'them', 'PRP', 'B-NP', 'O')
('back', 'back', 'RB', 'B-ADVP', 'O')
('on', 'on', 'IN', 'B-PP', 'O')
('their', 'their', 'PRP$', 'B-NP', 'O')
('normal', 'normal', 'JJ', 'I-NP', 'O')
('track.', 'track.', 'NN', 'I-NP', 'O')
